



World Health Organization
REGIONAL OFFICE FOR Africa

ANTIMICROBIAL RESISTANCE IN THE WHO AFRICAN REGION: a systematic literature review



ANTIMICROBIAL RESISTANCE IN THE WHO AFRICAN REGION: a systematic literature review

WHO Regional Office for Africa
ASSISTANT REGIONAL DIRECTOR CLUSTER
Antimicrobial Resistance Team
Brazzaville • 2021

CONTENTS

FOREWORD	v
ACKNOWLEDGEMENTS	vi
ABBREVIATIONS AND ACRONYMS	vii
EXECUTIVE SUMMARY	ix
1. INTRODUCTION	1
1.1 Background	1
1.2 Rationale	2
1.3 Scope and aim of this report	3
2. METHODOLOGY	3
2.1 Data sources and search strategy	3
2.2 Selection and rejection criteria	3
2.3 Selection procedure	4
2.4 Article quality assessment	4
2.5 Data extraction	4
2.6 Data analysis	5
3.1 Reviewed articles and main data characteristics	7
4. Discussion	16
4.1 Data interpretation and discussion	16
4.2 Data limitations	20
5. CONCLUSION AND RECOMMENDATIONS	20
5.1 Conclusion	20
5.2 Recommendations	21
REFERENCES	22

List of tables

Table 1: AMR patterns among gram-negative bacteria in the WHO African Region, 2016-2020	11
Table 2: AMR patterns among gram-positive bacteria in the WHO African Region, 2016-2020	13
Table 3: AMR in <i>Vibrio cholerae</i> in the WHO-African Region, 2016-2020	14


List of figures

Figure 1: Illustration of the search and selection flow of articles	6
Figure 2: Distribution of articles included in the review per WHO-AFR country	8



FOREWORD

Antimicrobial resistance (AMR) remains an alarming public health threat worldwide. It causes high mortality and morbidity especially in low- and middle-income countries where access to diagnostics is limited and antimicrobial prescription and intake remain inadequately regulated. It is estimated that there is a continual and yearly increase and worsening of AMR cases. This undermines the effectiveness of the available treatment options and thus contributes to the persistence of microbial infections. Antimicrobial resistance occurs through different mechanisms, which include spontaneous (natural) genetic mutations and horizontal transfer of resistant genes through deoxyribonucleic acid (DNA). Antimicrobial resistant microorganisms are found in people, animals and the environment and can spread globally. Therefore, since it is a global public health problem involving several sectors, it also requires a global solution in the context of the One Health approach to achieve adequate control through the prevention, reduction, and mitigation of drug-resistant infections. WHO urges Member States as well as international, regional and national health institutions to regularly report on AMR status to serve as an evidence base for informing strategies and devising efficient preventive and control interventions. Regular surveillance of AMR can provide timely information on its emergence and spread in a given setting. This report presents the status of AMR in Africa by analysing the main types of resistance and the underlying genes where possible. The report also includes a summary on the status of drug resistance for TB, HIV and malaria.



ACKNOWLEDGEMENTS

We acknowledge that this review report was conducted following a convenient and thorough methodology; and therefore, presents key information on current AMR status in the WHO African Region from 2016 to 2020. However, we also acknowledge the possible data bias that could result from missing AMR information in articles published in languages other than French or English. All the authors have approved the review procedure, data analysis, reporting and submission of the analysis outcomes.

Dr. Elizabeth Lindiwe Makubalo, Assistant Regional Director (ARD)/WHO AFRO.

Dr. Ali Ahmed Yahaya, AMR Team Lead/ARD Cluster, WHO AFRO;

Dr. Laetitia Gahimbare, AMR Technical Officer/Surveillance, Evidence and Laboratory Strengthening/ARD Cluster, WHO AFRO;

Dr. Walter Fuller, AMR Technical Officer/Antimicrobial Stewardship and Awareness/ARD Cluster, WHO AFRO;

Dr. Sheick Oumar Coulibaly, Diagnostics and Laboratory Services Team Lead/ARD Cluster, WHO AFRO;

Dr. Shakiwa Fausta Mosha, Laboratory Technical Officer-Universal Health Coverage-Communicable & Non-Communicable Diseases Cluster/HIV/AIDS-TB-Malaria;

Prof. Claude Mambo Muvunyi, Consultant WHO AFRO;

Prof. Nathalie Kouadio Guessennd, Consultant WHO AFRO;

Prof. Olga Perovic, Principal Pathologist at National Institute for Communicable Diseases (NICD) of South Africa, WHO Collaborating Centre for AMR ;

Prof. Hassiba Tali-Maamar, Head of the Medical Bacteriology and Antibiotic Resistance Surveillance Laboratory, Institut Pasteur of Algeria.



ABBREVIATIONS AND ACRONYMS

AMR	antimicrobial resistance
ARV	antiretroviral (drugs)
AST	antimicrobial susceptibility testing
BSAC	British Society for Antimicrobial Chemotherapy
BSI	bacterial bloodstream infection
CA-SFM	Comité de l'antibiogramme de la société française de Microbiologie
CDC	Centers for Disease Control and Prevention
CLSI	Clinical and Laboratory Standards Institute
CoNS	coagulase-negative Staphylococci
CSF	cerebrospinal fluid
ctxB	cholera enterotoxin subunit B precursor
DRC	Democratic Republic of the Congo
DRM	drug resistance mutation
E	Ethambutol
ESBL	extended-spectrum beta-lactamases
EUCAST	European Committee on Antimicrobial Susceptibility Testing
GLASS	Global Antimicrobial Resistance Surveillance System
H	isoniazid
HIV	human immunodeficiency virus
IPC	infection prevention and control
MIC	minimal inhibitory concentration
MISA	methicillin-intermediate <i>Staphylococcus aureus</i>
MRSA	methicillin-resistant <i>Staphylococcus aureus</i>
MSSA	methicillin-susceptible <i>Staphylococcus aureus</i>
NA	Not applicable
NRTI	Nucleoside reverse transcriptase inhibitor

NNRTI	Non-nucleoside reverse transcriptase inhibitor
PCR	polymerase chain reaction
PDR	Pretreatment HIV drug resistance
R	rifampicin
RAM	resistance-associated mutation
spp.	species
tcpA	toxin coregulated pilin precursor
TDR	transmitted HIV drug resistance
UTI	urinary tract infection
WHO	World Health Organization
WHO-AFR	World Health Organization African Region
WHO-AFRO	World Health Organization Regional Office for Africa
Z	pyrazinamide
Zot	zonula occludens toxin



EXECUTIVE SUMMARY

Antimicrobial resistance (AMR) imposes a huge burden on patients and health care systems in low- and middle-income countries. In Africa, the overall burden of AMR is not well understood or documented due to inadequate data. Therefore, this report presents the findings of a review of recently published data (from 2016 to 2020) on AMR in the WHO African Region (WHO-AFR) to help understand the current AMR status in this part of the continent.

Research was conducted on articles and reports relevant to the topic from different databases, search tools and repositories such as PubMed, EMBASE, Scopus, Cochrane Database for Systematic Reviews, African Journals Online Library, Google scholar, CDC and WHO websites. The systematic selection of research articles followed different inclusion and exclusion criteria that had been set beforehand. A total of 167 articles were included in the final review analysis. Analysis of the selected articles mainly focused on the reported data on infectious agents and their associated resistance phenotypes and genotypes, where possible. For an extended analysis and a better presentation of AMR data in the WHO African Region, the reported and shared AMR data in the Global Antimicrobial Resistance Surveillance System (GLASS) was also considered, including a brief account of AMR in HIV, TB and malaria from the most recent publications. The percentage of resistant bacterial isolates was calculated from the total number of tested isolates for each of the reported bacterial spp.

The results show that the majority of the bacteria were isolated from blood specimens. Among gram-negative bacteria, *Klebsiella* spp. remain the most common bacteria, and *E. coli* isolates reported a high resistance percentage for recommended first- and second-line antibiotics: amoxicillin (24.5%); ampicillin (23.5%); trimethoprim/sulfamethoxazole (22.5%); amoxicillin/clavulanic acid (13.2%); chloramphenicol (12.3%). Resistance to ciprofloxacin was (8.2%) [Table 1]. Low resistance rates were reported for imipenem (0.1-3%) and meropenem (0.1-2.5%) in gram-negative bacteria. For gram-positive bacteria, *Streptococcus pneumoniae* show high resistance percentages against the key tested antibiotics: trimethoprim/sulfamethoxazole (64.3%); oxacillin (32.2%); penicillin (23.2%); tetracycline (28.3%); amoxicillin (20.6%); ampicillin (19.3%); chloramphenicol (19.3%); amoxicillin/clavulanic acid (17.4%); ciprofloxacin (14.8%); gentamicin (13.5%); doxycycline (1.9%); and erythromycin (1.9%).

Mono-resistant and multidrug-resistant (MDR) cases of HIV, TB and malaria are also reported from the latest research findings in Africa.

This report presents the most recent in-depth review of the situation of AMR in relation to the most commonly prescribed antibiotics in the African Region. The review findings highlight the alarmingly persistent cases of AMR in the African Region, and the urgent need to implement the national action plans to combat AMR and improve surveillance programmes in each of the 47 Member States, as well as support IPC measures, raise stakeholder awareness and optimize antimicrobial stewardship, sharing and reporting of AMR data.

1. INTRODUCTION

1.1 Background

Antimicrobial resistance (AMR) is defined as the inherited or acquired ability of a microorganism to stop the antimicrobial drug from working against it to the extent that it cannot be used any longer. The available drugs used to treat microbial infections become less effective or ineffective and lead to the persistence and spread of the resistant organisms causing infections [1]. The bacteria overcome the effects of antimicrobial drugs (such as antibiotics) through five main biochemical mechanisms of resistance. These include enzymatic modification or destruction of the antibiotic; modification of the antibiotic target site; mimicking the antibiotic target with similar biochemical functions or overproduction of the antibiotic target; decreasing the antibiotic penetration; and elimination of the antibiotic from the cell by efflux pumps [2]. Bacteria may have multiple resistance mechanisms [3]. The main factors exacerbating the issue of AMR in Africa include the limited supply or access to antimicrobial drugs, while those that are available might be of poor quality or counterfeit. In addition, in low-resource settings such as Africa, antimicrobials including antibiotics can be sold over the counter or used in feeding animals as prophylaxis or growth promoters [4]. The issue of lack of regulation and quality control of drugs may be exacerbated by poor infection prevention and control (IPC) and water, sanitation and hygiene (WASH) interventions and can accelerate the spread of drug-resistant microorganisms.

Antibiotic susceptibility testing (AST) remains the standard diagnostic method for detecting bacterial resistance and guides clinicians in the appropriate and timely treatment of bacterial infections [5, 6]. AST results are crucial for surveillance studies to generate epidemiological data on bacterial pathogens and associated AMR. These data constitute the baseline information for national, regional and global strategies to contain the spread of AMR.

The disk diffusion test remains the recommended method for testing antibiotic susceptibility for most bacteria. This method is based on measuring and reporting the bacterial inhibition zone. The zone diameter establishes a measurement of the susceptibility of the bacterium to the antibiotic. The disc diffusion method may not be used for all organisms due to the inability of some bacteria to grow in solid media. Methods that determine the minimal inhibitory concentration (MIC) in fastidious or slow-growing bacteria are recommended [5]. The MIC is defined as the lowest concentration of the antibiotic that can inhibit or stop the growth of the bacteria [5]. The broth microdilution test and the Epsilometer test (E-test) are the most frequently used methods for MIC determination, and compulsory for some pathogens such as susceptibility testing of penicillin-resistant *Streptococcus pneumoniae* to guide antimicrobial therapy [7]. Next to conventional microbiological culture, molecular methods such as PCR (conventional PCR or real-time PCR) and sequencing (targeted sequencing or whole genome sequencing) are used in molecular characterization of AMR and determination of resistance markers [8-21].

There are guidelines on the standardized values for zone diameters (disc diffusion) and MIC breakpoints that are provided by different institutional committees such as the Clinical and Laboratory Standards Institute (CLSI) [22], the European Committee on Antimicrobial Susceptibility Testing (EUCAST) [23], the French Society for Microbiology (CA-SFM) [24] and the British Society for Antimicrobial Chemotherapy [25].

Only a few reports and publications are available on the problem of AMR on the continent. Three main review articles have been published since 2001: two of them were conducted on the broad clinically relevant bacteria [26, 27], and one assessed the issue of AMR more specifically in children with sepsis not only in Africa but also covering all other resource-limited countries worldwide [28]. In addition, only nine countries of the African Region were able to report AMR data in the Global Antimicrobial Resistance Surveillance System (GLASS) over two recent years (2016-2018). There is a still inadequate coordination and implementation of policies to assess and monitor the situation of AMR in Africa despite the availability of GLASS. In these resource-limited settings, treatment is mostly based on presumptive clinical diagnosis with empirical choice of the antibiotic, but not on AST results. In 2020, the COVID-19 pandemic further contributed to the increased spread of AMR due to inappropriate use of antibiotics for case management of patients [29].

Most low-resource settings still experience the issue of inadequate infrastructure, lack of technical skills and essential supplies for the optimal diagnosis and treatment of AMR [30]. This leads to an increase of infectious diseases and associated AMR in low- and middle-income countries (LMICs). Detection of AMR in LMICs is insufficient even in some national reference laboratories and reflects lack of laboratory capacity to support diagnostic methods.

1.2 Rationale

AMR remains a significant threat to the treatment of bacterial infections globally and most importantly in low- and middle-income settings including Africa. The AMR threat adds to the existing higher burden of bacterial infections in such settings and low access to adequate diagnostics, specifically at intermediate and peripheral levels of the health system [1]. The establishment of microbiology laboratories in low-resource settings including Africa can improve patient management and provide the required surveillance data for developing local or regional treatment guidelines, and support the containment of AMR.

1.3 Scope and aim of this report

Understanding the recent status of AMR surveillance and trends of resistance in Africa could improve clinical practice by guiding the clinician's choice of the right antibiotic and informing decision-making for African Region Member States, WHO-AFRO, partners and stakeholders. To this end, a review of the currently available and published data on the aetiology of bacterial infections and their associated AMR patterns in the WHO African Region from 2016 to 2020 was conducted. The analysis focused on the AST methods currently in use, types of recent AMR patterns and regional distribution of resistance patterns. The report also includes a summary on the status of drug resistance for TB, HIV and malaria. This review report proposes recommendations, future options and interventions to contain AMR in the WHO African Region.

2. METHODOLOGY

2.1 Data sources and search strategy

Two freely accessible scientific web search engines, PubMed and Google scholar, were searched with the aim of capturing published research data on AMR. The search was extended to the entire African continent and later excluded articles from countries, which are not part of the WHO African Region. The following keywords related to the review topic were used: "Antimicrobial Resistance Africa", "Antimicrobial Susceptibility Africa", "Surveillance Africa", "Diagnostic Africa", and "Bacteria Diagnostic Africa". These five search keywords were entered in PubMed and Google scholar, respectively. All articles on AMR in the WHO African Region were then retrieved. The same search strategy was repeated for the second round of the search with the use of the same key words but with the name of each country of the African Region added next to it with each search.

2.2 Selection and rejection criteria

Retrieved articles were retained if they met and satisfied the following inclusion criteria: published between 2016 and 2020; published in English or French; reporting AMR research data in humans; conducted in countries of the WHO African Region; free accessibility of their abstracts and full texts; reporting data on AST; providing details on the total number of studied isolates; and were case reports or case series. Conversely, retrieved articles were rejected based on the following exclusion criteria: not providing information on the total number of studied isolates; conducted in other regions or countries than the WHO African Region; used on non-human subjects; conducted as randomized control trials of antibiotics, surveillance studies on antibiotic use/misuse, or as molecular investigations of AMR molecular markers; not having freely accessible abstracts or full text; or reviews of given types of AMR. In addition, reference lists of potential research articles retained at this stage were subsequently scrutinized for inclusion

criteria, and those meeting the criteria were added to the final list of potential research articles to be reviewed and included in this report.

2.3 Selection procedure

From the initially retrieved 48 003 articles, 7261 were excluded because they were either books or they did not have an abstract; 40 013 articles were excluded because they did not fit in our review topic or lacked free full text versions. A total of 342 articles were subsequently excluded because they were conducted on non-human subjects; as reviews of AMR or simply as molecular investigations of AMR markers. At the next stage, 240 articles were excluded because they were either published before 2016, showing a low quality assessment score or conducted from a country outside the WHO African Region. The total of 147 articles that were retained was also added to the other 20 that were identified from all their respective reference lists. This yielded a total of 167 articles that were analysed in this review. A complete description of all the steps followed to select the final articles that were included in this report is found on the flowchart presented here below.

2.4 Article quality assessment

The quality of each of the 167 selected articles was assessed based on the methodological quality and appropriateness for inclusion without limiting the consideration to their generated results. The criteria for quality assessment that were followed are the following:

- (a) Is the research question clear and adequate to the study?
- (b) Is the study design used appropriate to the set research question?
- (c) Was the sampling method appropriate for the set research question and design?
- (d) Were data collected and managed systematically?
- (e) Were the collected data analysed appropriately?

2.5 Data extraction


The extracted data from the 167 reviewed articles were compiled in an Excel database (Excel 2016) that was designed for the purpose of this review report. The data that were extracted from articles are related to: the first author, publication year, title, DOI/PMID/Link, WHO-AFR country, study/data collection period, study objective, study design, study subjects, inpatient or outpatient, type of sample, age group, reported bacteria, infection/syndrome. Additionally, the extracted data included source of infection (health care- or community-acquired infection); investigation method (phenotypic or genotypic); bacterial identification method; AST method; tested antibiotics; and AST guidelines (Annex 1).

2.6 Data analysis

The total number of clinical bacterial isolates tested in each selected article was extracted and the overall number of isolates tested was calculated for susceptibility against the key antibiotics. From this step, the percentage of resistant bacterial isolates could then be deduced from the total number of tested isolates for each of the reported bacteria spp.

For an extended analysis and a better presentation of AMR data on the WHO African Region, reported and shared AMR data from the WHO African Region in GLASS were also considered. GLASS was launched in 2015 at the behest of the Sixty-eighth World Health Assembly in resolution WHA68.7, with the aim of supporting the global action plan on AMR (GAP-AMR), and specifically the second objective of the GAP-AMR, which is to strengthen knowledge through surveillance and research and to enhance existing activities [<https://www.who.int/glass/en/>] [31].

Figure 1: Illustration of the search and selection flow of articles



3. RESULTS

3.1 Reviewed articles and main data characteristics


A total of 48 003 potential articles were reviewed from the two scientific databases, PubMed and Google scholar as described above, and the selection process yielded a total number of 167 articles [Annex 1] that met the inclusion criteria, and were included in the analysis [9, 12, 20, 32-215]. The majority of the final selected articles were published in 2019, (38, 22.6%), with most of them having a collection period for the reported isolates falling before 2016 (95, 56.5%). As shown in Figure 2, a high number of the reviewed articles were conducted in Ethiopia (76, 45.2%) with the rest of the countries represented by a low number of articles; for example, Mali, Niger, and Central African Republic, etc. are represented by 1 (0.6%) [Annex 2].

Considering the type of investigation (phenotypic or genotypic and phenotypic), more studies have used the phenotypic investigation method (123, 73.7%) which mostly relies on the standard microbiological culture, followed by a combination of both phenotypic and genotypic investigations (44, 26.3%) [Annex 2].

For the interpretation of the AST data, most of the studies used the CLSI guidelines (129, 76.8%), followed by those of EUCAST (17, 10.1%), whereas the CLSI and BSAC guidelines were the least used (2, 1.2%) or not mentioned in the rest of the articles. In contrast, for the AST methods, the majority of the reviewed studies used disc diffusion (114, 67.8%), and for bacterial identification, the majority of the reviewed studies used the common standard for microbiological culture (105, 62.5%).

The number of bacteria isolates reported in the reviewed articles varies from one medical condition (infection/syndrome) to another, and most of them are linked to BSI [Annex 3]. Thus, *Acinetobacter baumannii* was isolated in 65.9% of cases from samples of patients with BSI (65.9%). This is also the case for *Escherichia coli* (49.8%), *Group A Streptococcus* (75%), *Klebsiella pneumoniae* (67.2%), *Pseudomonas spp.* (38.5%), *Salmonella enterica* serovars Typhi (S. Typhi) (64%), non-typhoidal *Salmonella* serovars (50.4%), *Shigella spp.* (74.3%), *Staphylococcus aureus* (62.6%), and *Streptococcus spp.* (68.4%). The situation was different with *Proteus mirabilis*, which in 61% of cases was isolated from samples of patients with an upper urinary tract infection.

Figure 2: Distribution of articles included in the review per WHO-AFR country



3.2 Data analysis

Analysis of the data includes six main themes. Theme 1 presents a summary of the reported AMR data in GLASS from African countries from previous years, 2016 to 2018 [Annex 4]. The second and third themes present the mainly reported bacterial AMR patterns from the reviewed articles

among gram-negative and gram-positive bacteria, respectively. The fourth theme presents the AMR in *Vibrio cholerae* in Africa, 2016-2020; the fifth theme presents the main underlying genetic markers of the phenotypic AMR reported among the common gram-negative and gram-positive bacteria in the WHO African Region; and the last theme (sixth) presents data on AMR in HIV, TB and malaria in the WHO African Region.

Theme 1: AMR patterns (number of resistance cases (%)) from GLASS_WHO-AFR 2016-2018

The establishment of GLASS was requested by Member States upon the adoption of the WHO Global action plan on AMR in May 2015 (resolution WHA68.7). GLASS promotes a standardized approach to the collection, analysis and sharing of AMR, AMC and AMU data; a One Health model for AMR surveillance; and generation of data to inform AMR burden estimates. It is the first global system to incorporate official national data from surveillance of AMR in eight selected bacterial pathogens that cause common infections in humans, namely *Acinetobacter spp.*; *Escherichia coli*; *Klebsiella pneumoniae*; *Neisseria gonorrhoeae*; *Salmonella spp.*; *Shigella spp.*; *S. aureus* and *Streptococcus pneumoniae*. GLASS relies on continuous data sharing and global collaboration, harmonization and coordination among all partners involved in the implementation of AMR surveillance. Any new AMR data detected that may influence surveillance and control practices are communicating between GLASS networks. That includes resistance phenotypes not reported or very rare, new resistance genotypes associated with resistance mechanisms that can have a high impact on public health, high potential for propagation and health impact, and serious challenges in detecting and monitoring in the laboratory.

In the WHO African Region, the number of countries enlisted increased from seven in 2016 to 28 in 2020. During this period, WHO launched three data calls and the number of countries from the African Region that responded was nine in 2017 (report on 2016 AMR data), 14 in 2018 (2017 AMR data) and 15 in 2019 (2018 AMR data). They provided information on their national AMR surveillance systems and in addition, some reported on AMR rates: five countries in 2017; six in 2018; and seven in 2019.

The summary status of national surveillance systems showed that by 2019, thirty per cent of responding countries had established or were in the process of establishing a National Coordination Centre for AMR Surveillance, while 32% had designated National Reference Laboratories (NRLs). Almost all NRLs were participating in an External Quality Assessment (EQA) scheme and performing AST according to internationally recognized standards.

AMR isolates were mostly reported from the East, Southern and Western subregions of Africa. During this period, the number of surveillance sites increased from 35 to 93, while the number of patients with suspected infections moved from 4438 in 2017 to 26 628 in 2018 (2018 AMR

data). For the latter, 91% of AST results were available and the eight types of bacteria surveyed by GLASS were described from four infection sites: bloodstream (82%); urinary tract (10%); gastroenteric (6%) and genital (2%). *Staphylococcus aureus* and *Klebsiella pneumoniae* were mainly isolated from bloodstream infections; they accounted for 30% and 29%, respectively. *E. coli* was predominant in urinary tract infections (83%).

GLASS reports highlighted high resistance patterns in the WHO African Region; however, data are not yet representative of the national/regional level to be shared in this report. Nevertheless, they provide useful information that can be used for capacity building and advocacy (Annex 4).

Theme 2: AMR patterns among gram-negative bacteria in the WHO African Region, 2016-2020.

Among the commonly reported medical bacteria pathogens, 10 gram-negative bacteria species and serovars were selected from all other gram-negative bacteria reported in all the 167 reviewed articles, and their AMR data are presented in Table 1 below. They are *Acinetobacter baumannii*, *Escherichia coli*, *Haemophilus* spp., *Klebsiella* spp., *Neisseria* spp., *Proteus mirabilis*, *Pseudomonas* spp., *Salmonella* Typhi, non-typhoidal *Salmonella* serovars and *Shigella* spp. These gram-negative bacteria were tested against 28 different antibiotics: amikacin, amoxicillin/clavulanic acid, amoxicillin, ampicillin, azithromycin, cefotaxime, ceftazidime, ceftriaxone, cefuroxime, chloramphenicol, ciprofloxacin, trimethoprim/sulfamethoxazole, doxycycline, erythromycin, gentamicin, imipenem, levofloxacin, meropenem, nalidixic acid, nitrofurantoin, norfloxacin, ofloxacin, oxacillin, penicillin, piperacillin, piperacillin/tazobactam, tetracycline and tobramycin. Among all the 10 tested bacteria species, *Klebsiella* spp. remain the most tested bacteria with a high number of isolates and generally the most resistant. *E. coli* presents most of the reported high AMR percentages (%) for amoxicillin (24.5%), ampicillin (24%), amoxicillin/clavulanic acid (13.2%), chloramphenicol (12.5%), ciprofloxacin (8.2%) and trimethoprim/sulfamethoxazole (22.5%) [Table 1]. The highest overall phenotypic resistance for imipenem is reported in *E. coli*, whereas for meropenem, *E. coli* and *Haemophilus* spp. show an equal resistance proportion at 2.5% [Table 1].

Table 1: AMR patterns among gram-negative bacteria in the WHO African Region, 2016-2020

Antibiotic	<i>Acinetobacter baumannii</i> n (% resistance)	<i>Escherichia coli</i> (% resistance)	<i>Haemophilus spp.</i> n (% resistance)	<i>Klebsiella spp.</i> n (% resistance)	<i>Neisseria spp.</i> n (% resistance)	<i>Proteus mirabilis</i> n (% resistance)	<i>Pseudomonas spp. n</i> (% resistance)	<i>Salmonella Typhi</i> n (% resistance)	Non-typhoidal <i>Salmonella</i> serovars n (% resistance)	<i>Shigella spp.</i> n (% resistance)
Amikacin	42 (1.9)	30 (2.5)	5 (1.4)	22 (1.3)	20 (0.7)	52 (0.6)	11 (0.8)	14 (0.7)	27 (0.2)	10 (04)
Amoxicillin/clavulanic acid	NA	159 (13.2)	32 (9)	61 (3.6)	16 (0.6)	64 (0.7)	NA	16 (0.8)	0 (0)	12 (0.5)
Amoxicillin	NA	294 (24.5)	4 (1.1)	NA	26 (0.9)	184 (2)	NA	79 (3.7)	54 (0.4)	18 (08)
Ampicillin	NA	282 (23.5)	110 (30.8)	NA	12 (0.4)	104 (1.1)	NA	67 (3.2)	36 (0.3)	122 (5.2)
Azithromycin	2 (0.1)	24 (2)	7 (2)	6 (0.3)	28 (1)	8 (0.1)	7 (0.5)	0 (0)	0 (0)	16 (0.7)
Cefotaxime	100 (4.5)	108 (9)	8 (2.2)	61 (3.5)	24 (0.9)	60 (0.7)	98 (7.4)	0 (0)	108 (0.8)	20 (0.9)
Ceftazidime	91 (4.1)	87 (7.2)	3 (0.8)	56 (3.2)	6 (0.2)	80 (0.9)	39 (2.9)	11 (0.5)	63 (0.5)	0 (0)
Ceftriaxone	84 (3.8)	123 (10.2)	30 (8.4)	57 (3.3)	14 (0.5)	54 (0.6)	40 (3)	0 (0)	171 (1.2)	6 (0.3)
Cefuroxime	85 (3.8)	120 (10)	11 (3.1)	61 (3.5)	16 (0.6)	80 (0.9)	6 (0.5)	9 (0.4)	27 (0.2)	14 (0.6)
Chloramphenicol	NA	147 (12.3)	38 (10.6)	72 (4.2)	20 (0.7)	120 (1.3)	NA	53 (2.5)	630 (4.5)	44(1.9)
Ciprofloxacin	34 (1.5)	99 (8.2)	24 (6.7)	34 (2)	94 (3.4)	34 (0.4)	26 (2)	0 (0)	90 (0.6)	0 (0)
Trimethoprim/sulfamethoxazole	90 (4)	270 (22.5)	93 (16.1)	77 (4.5)	224 (8)	142 (1.6)	NA	62 (2.9)	630 (4.5)	186 (8)
Doxycycline	9 (0.4)	192 (16)	8 (2.2)	77 (4.5)	18 (0.6)	10 (0.1)	4 (0.3)	9 (0.4)	63 (0.5)	8 (0.3)
Erythromycin	6 (0.3)	273 (22.7)	5 (1.4)	68 (3.9)	12 (0.4)	6 (0.1)	8 (0.6)	6 (0.3)	27 (0.2)	20 (0.9)
Gentamicin	71 (3.2)	117 (9.7)	69 (19.3)	51 (3)	76 (2.7)	46 (0.5)	39 (2.9)	12 (0.6)	198 (1.4)	30 (1.3)
Imipenem	9 (0.4)	36 (3)	3 (0.8)	6 (0.3)	4 (0.1)	20 (0.2)	16 (1.2)	3 (0.1)	54 (0.4)	16 (0.7)
Levofloxacin	7 (0.3)	87 (7.2)	6 (1.7)	25 (1.4)	10 (0.4)	104 (1.1)	35 (2.6)	10 (0.5)	63 (0.5)	12 (0.5)
Meropenem	51 (2.3)	30 (2.5)	9 (2.5)	11 (0.7)	6 (0.2)	11 (0.1)	17 (1.3)	3 (0.1)	45 (0.3)	10 (0.4)
Nalidixic acid	3 (0.1)	108 (10)	10 (2.8)	45 (2.6)	20 (0.7)	138 (1.5)	88 (6.7)	15 (0.7)	180 (1.3)	4 (0.2)
Nitrofurantoin	70 (3.1)	72 (6)	5 (1.4)	34 (2)	14 (0.5)	132 (1.5)	86 (6.5)	6 (0.3)	72 (0.5)	20 (0.9)
Norfloxacin	44 (2)	105 (8.7)	10 (2.8)	41 (2.4)	10 (0.4)	0 (0)	28 (2.1)	9 (0.4)	99 (0.7)	16 (0.7)
Ofloxacin	3 (0.1)	123 (10.2)	4 (1.1)	27 (1.6)	16 (0.6)	78 (0.9)	2 (0.2)	5 (0.2)	747 (5.3)	8 (0.3)
Oxacillin	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Penicillin	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Piperacillin	60 (2.7)	204 (17)	10 (2.8)	11 (0.6)	18 (0.6)	16 (0.2)	7 (0.5)	2 (0.1)	90 (0.6)	14 (0.6)
Piperacillin/tazobactam	43 (1.9)	93 (7.7)	8 (2.2)	6 (0.3)	8 (0.3)	6 (0.1)	24 (1.8)	6 (0.3)	45 (0.3)	12 (0.5)
Tetracycline	83 (3.7)	258 (21.5)	35 (9.8)	78 (4.5)	202 (7.2)	156 (1.7)	NA	53 (2.5)	423 (3)	130 (5.6)
Tobramycin	2 (0.1)	126 (10.5)	10 (2.8)	55 (3.2)	6 (0.2)	4 (0.04)	5 (0.4)	7 (0.3)	27 (0.2)	18 (0.8)

NA: Not applicable; since a natural resistance exists for this bacterial species towards the tested antibiotic type, while on the list of antibiotics, highlighted in bold are those recommended as first- or second-line antibiotics.

Theme 3: AMR patterns among gram-positive bacteria in the WHO African Region, 2016-2020

Conversely, for gram-positive bacteria (data presented in Table 2 below), the three main medically important gram-positive bacteria were assayed for antimicrobial susceptibility. These gram-positive bacteria are Group A *Streptococci*, *Staphylococcus aureus* and *Streptococcus pneumoniae*. They were tested against the following 26 different antibiotics: amikacin, amoxicillin, ampicillin, amoxicillin/clavulanic acid, cefotaxime, cefoxitin, ceftazidime, ceftriaxone, cefuroxime, chloramphenicol, ciprofloxacin, clindamycin, trimethoprim/sulfamethoxazole, doxycycline, erythromycin, gentamycin, imipenem, levofloxacin, nalidixic acid, nitrofurantoin, norfloxacin, ofloxacin, oxacillin, penicillin, tetracycline and vancomycin.

Streptococcus pneumoniae show high resistance percentages against the key tested antibiotics: Amoxicillin (20.6%); ampicillin (19.3%); amoxicillin/clavulanic acid (17.4%); chloramphenicol (19.3%); ciprofloxacin (14.8%); trimethoprim/sulfamethoxazole (64.3%); doxycycline (1.9%); erythromycin (1.9%); gentamicin (13.5%); oxacillin (32.2%); penicillin (23.2%); and tetracycline (28.3%).

Table 2: AMR patterns among gram-positive bacteria in the WHO African Region, 2016-2020

Antibiotic	<i>Group A streptococci</i> n (% resistance)	<i>Staphylococcus aureus</i> n (% resistance)	<i>Streptococcus pneumoniae</i> n (% resistance)
Amikacin	NA	1 300 (3)	NA
Amoxicillin	25 (1.8)	8 800 (20)	1 600 (20.6)
Ampicillin	18 (1.3)	9 500 (21.6)	1 500 (19.3)
Amoxicillin/clavulanic acid	5 (0.4)	3 300 (7.5)	1 350 (17.4)
Cefotaxime	2 (0.1)	3 800 (8.6)	650 (8.4)
Cefoxitin	3 (0.2)	2 000 (4.6)	150 (1.9)
Ceftazidime	8 (0.6)	6 000 (13.7)	250 (3.2)
Ceftriaxone	4 (0.3)	4 800 (10.9)	600 (7.7)
Cefuroxime	7 (0.5)	5 900 (13.4)	800 (10.3)
Chloramphenicol	36 (2.6)	3 400 (7.7)	1 500 (19.3)
Ciprofloxacin	28 (2)	3 100 (7.1)	1 150 (14.8)
Clindamycin	5 (0.4)	2 100 (4.8)	800 (10.3)
Trimethoprim/sulfamethoxazole	43 (3.1)	7 468 (17)	5 000 (64.3)
Doxycycline	2 (0.1)	6 500 (14.8)	150 (1.9)
Erythromycin	20 (1.4)	4 300 (9.8)	1 050 (13.5)
Gentamicin	NA	2 800 (6.4)	NA
Imipenem	5 (0.4)	1 800 (4.1)	550 (7.1)
Levofloxacin	7 (0.5)	1 500 (3.4)	350 (4.5)
Nalidixic acid	9 (0.6)	8 300 (18.9)	150 (1.9)
Nitrofurantoin	10 (0.7)	2 200 (5.0)	250 (3.2)
Norfloxacin	34 (2.4)	4 000 (9.1)	450 (5.8)
Ofloxacin	3 (0.2)	3 600 (8.2)	300 (3.9)
Oxacillin	2 (0.1)	4 400 (10)	2 500 (32.2)
Penicillin	11 (0.8)	10 000 (22.8)	1 800 (23.2)
Tetracycline	35 (2.5)	5 400 (12.3)	2 200 (28.3)
Vancomycin	2 (0.1)	1 200 (2.7)	600 (7.3)

NA: Not applicable, since a natural resistance exists for these bacterial species towards the tested antibiotic type, while on the list of antibiotics, highlighted in bold are the recommended first- or second-line antibiotics. Resistance to b-lactam in group A streptococci is reported in some studies; however, these isolates were not speciated and this review is therefore unable to specifically identify the *Streptococcus pyogenes* isolates within this group

Theme 4: AMR in *Vibrio cholerae* in the WHO African Region, 2016-2020

The serotyping of most of the *Vibrio cholerae* isolates have shown that the circulating *Vibrio cholerae* strains belong to the subtype O1 and Ogawa serotype [32, 86, 90, 216, 217].

The circulating *Vibrio cholerae* strains in Africa carry mostly reported resistance markers for the currently recommended antibiotics for treatment. The resistance rates for sulphamethoxazole-trimethoprim and ampicillin ranged from 75% to 100%, while no resistance for ciprofloxacin was observed for any of the isolates.

Genotypic investigations reported resistance markers to ampicillin [90, 216, 217] and trimethoprim/sulfamethoxazole [32, 90, 216, 217]; these were the most commonly reported among *Vibrio cholerae* isolates.

The most phenotypic resistance and associated genetic markers of *Vibrio cholerae* isolates (% of all *Vibrio cholerae* isolates) are presented in Table 3 below.

Table 3: AMR in *Vibrio cholerae* in the WHO-African Region, 2016-2020

Phenotypic resistance	Genetic markers (% all <i>Vibrio cholerae</i> isolates)
Ampicillin	ctxB (93.5%)
Trimethoprim/Sulfamethoxazole	tcpA (77.5%)
Ciprofloxacin	zot (77.5%)

Genotypic investigations reported the following associated resistance genes: ZOT (77.5%) [32], tcpA (77.5%) [32] and ctxB (93.5%) [32, 217].

Theme 5: Genetic markers underlying phenotypic AMR in the WHO African Region

A compilation of the genomic data from the genotypic investigation-based studies shows the genetic markers that are frequently reported to be associated with the common AMR phenotypes among gram-negative and gram-positive bacteria in the WHO African Region. The AMR genes and mutations associated with extended-spectrum β -lactamase (ESBL), metallo- β -lactamases (MBL), carbapenemase, decreased ciprofloxacin susceptibility (DCS) and methicillin resistance, are mostly reported among *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, *Escherichia coli*, *Salmonella Typhi* and *Staphylococcus aureus*, respectively. For the ESBL genes, *blaCTX-M*, *blaTEM* and *blaSHV* are highly reported at 522 (60.3%), 203 (51%) and 604 (70 %), respectively [Annex 5]. The same genes are also detected in *Escherichia coli*, but at lower rates compared to *Klebsiella pneumoniae*. The *blaNDM* among other genes associated with metallo-beta-lactamase production remains the mostly widely reported and is found at higher

frequencies in *Klebsiella pneumoniae*. Furthermore, the *blaOXA*, *SCCmec* and *gyrA* mutation associated with carbapenemase, MRSA and DCS phenotypes are reported at 336 (49%), 116 (21.4%) and 487 (25%) respectively in *E. coli*, *S. aureus* and *S. Typhi* [Annex 5].

Theme 6: AMR in HIV, TB and malaria

The circulating HIV strains in Africa include the nucleoside reverse transcriptase inhibitor- (NRTI) and non-nucleoside reverse transcriptase inhibitor- (NNRTI) resistant variants and they are frequently observed among ART-naive and experienced HIV-1-infected patients on the continent; the prevalence of pre-treatment drug resistance (PDR) to HIV, NRTIs and NNRTIs is high [218-252]. Different surveillance studies on the continent have also reported levels of NNRTI PDR in Cameroon, Namibia, Uganda and Zimbabwe. Various research reports from Africa show an increase of NNRTI and NRTI PDR associated with prior ARV exposure; this was also reported in Mozambique, Eswatini, South Africa, Uganda and Zimbabwe. The prevalence of NNRTI PDR of above 10% is observed in Africa and ranges from 8% in Cameroon to 15% in Uganda [WHO, HIV drug resistance report 2019]. The emergence of drug resistant variants of HIV-1 is associated with mutations within the HIV-1 pol genes that encode the molecular targets for major antiretroviral drugs (ARV). Resistance to lamivudine, tenofovir, efavirenz was reported at high rates in countries of the WHO African Region, specifically in Malawi [253]. The prevalence of HIV-associated drug resistance mutations is high in Central Africa, followed by West Africa, with the NNTI mutations high in East Africa followed by West, Central and Southern Africa (16.3%). The major nucleoside reverse transcriptase inhibitor mutations in all four African subregions were M18V and K65R gene mutations [254].

In Africa, the most frequently reported TB resistance cases are mono-resistance and multi-drug resistance (MDR-TB) [255]. In African countries in 2019, an estimated 2.6% (95% confidence interval [CI]: 1.6–3.7 %) of new cases and 11% (95% CI: 2.2–27%) of previously treated cases had MDR/RR-TB. TB mono-resistance is high for isoniazid, followed by rifampicin, and is mostly reported from Zimbabwe and Eswatini; whereas high rates of MDR are reported from Côte d'Ivoire, Ethiopia, Lesotho, Namibia, Zambia and Zimbabwe.

The associated resistance gene mutations that were reported are found in *katG*, *rpoB* (n=3591), *rrs*, *inhA*, *pncA* and *embB*; and the commonest lineage families circulating in Africa are T, LAM, Beijing, Cameroon, CAS and H. Mono-resistance to pyrazinamide, bedaquiline and clofazimine is found and associated with mutations in *pncA*, *atpE*, *Rv1979c*, *Rv0678* and *pepQ* genes respectively [256-267]. MDR-TB, characterized by resistance to isoniazid and rifampicin, is also reported and associated with mutations in the gene loci *rpoB*, *katG*, and *inhA* [256, 265].

Resistance to antimalarial drugs has also been reported on the African continent with clinical and parasitological failure above 30% for chloroquine (CQ) and less than 3% for artemisinin-based combination therapy (ACT) and their associated resistant genes and gene mutations: chloroquine resistance associated with *Pfcrt* 76Thr primary mediator and *pfmdr1* 86Tyr and 1246Ty mutations; piperaquine resistance associated with *pfcrt* mutations; quinine associated with mutations in *pfmdr1*, *pfmdr6*, *pfcrt*, *pfmrp1*, and *pfnhe1*; mefloquine resistance associated with the increased *pfmdr1* copy number; dihydroartemisinin (DHA), artemether and artesunate all associated with *K13PD* mutations; atovaquone associated with mutations in cytochrome b particularly 268Ser, 268Cys and 268Asn; pyrimethamine associated with *pfdhfr* mutations (108Asn, 51Ile, 59Arg, and 164Leu); proguanil associated with *pfdhfr* mutations (108Asn, 51Ile, 59Arg, and 164Leu); sulfadoxine associated with *pfdhps* mutations (primarily 437Gly, 540Glu, 581Gly); and sulfadoxine-pyrimethamine resistance [268-282]. The most recent antimalarial drug resistance in Africa remains artemisinin resistance that was recently reported in Rwanda and for the first time in Africa [283].

4. DISCUSSION

4.1 Data interpretation and discussion

The findings described in this review report are mainly AMR data that have been extracted and analysed from a total of 167 articles published between 2016 and 2020. The articles are outcomes of microbiology research that were conducted in Africa. Available data that have been shared in GLASS from 2016 to 2018 from a limited number of WHO-AFRO countries were also considered. In addition, a brief account of *Vibrio cholerae* in the WHO African Region was provided, based on what has been reported from the reviewed articles. Furthermore, the analysis was extended to other important infections on the African continent such as HIV, TB and malaria, with more emphasis on recent publications on their phenotypic and genotypic resistance.

Only a few countries from the African Region have shared their AMR data through GLASS, and this obviously contributes the most to the frequently encountered issue of AMR data paucity in Africa. For the 167 reviewed articles that constituted this review, it was observed that different panels of antibiotics, AST methods and different AST interpretation guidelines were used. Thus, standardization of the microbiological identification and AST methods, and sharing of AMR data are required to enable regional and international organizations such as WHO to closely monitor the extent and evolution of the AMR problem in Africa.

These AMR cases constitute major and ongoing public health threats; they are also highlighted in the WHO list of critical-priority AMR bacteria for which new research, discovery, and development of new antibiotics are highly needed [284]. Therefore, timely and continuous surveillance of bacterial and TB infections, reporting and sharing of AMR data are needed in Africa to guide the required new approaches for control and treatment of bacterial infections.

In this review, the susceptibility results from selected articles were evaluated with caution, given the inconsistencies in the choice of antibiotic combinations in the various articles. For instance, in some cases, amoxicillin was tested and reported for *Acinetobacter*, and ampicillin and amoxicillin for *Klebsiella* spp., although these bacteria have acquired a natural resistance to the tested antibiotics. In the same trend of natural resistance forms, oxacillin and penicillin were also tested in gram-negative bacteria, although they are known to remain inactive to these bacteria. *Citrobacter* remains an opportunistic bacterium and not a true medically important bacterium in humans [22, 285, 286]. In all these cases, the compiled, corresponding extracted data were recorded as not applicable “NA” in Tables 1 and 2 of the results.

Based on the review report, among gram-negative bacteria, resistance in *E. coli*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, *Neisseria* spp., non-typhoidal *Salmonella* serovars and *Vibrio cholerae* remains significant in Africa. ESBLs and carbapenems resistance are reported at low but alarming rates in Africa.

The results of this review mirror those from previous reviews conducted on AMR in Africa and published in 2014 [27] and 2017 [26]. For instance, resistance of the key gram-negative bacteria such as *Enterobacteriaceae* to the commonly recommended first- and second-line antibiotics is reported in the results of this review as in the two previous review studies. In addition, for gram-positive bacteria, resistance of *Staphylococcus aureus* to oxacillin and resistance rates to penicillin in *Streptococcus pneumoniae* observed in the results of this review were previously reported [26, 27].

This underscores the persistence of the AMR problem in the WHO African Region and that choice of antimicrobial therapy based on WHO Access, Watch and Reserve (AWaRe) classification Access and Watch may be limited, and could constitute a huge burden and result in high mortality in Africa.

The present findings also confirm the presence of some important genetic markers for the key resistance forms such as ESBL and carbapenem production among pathogens causing BSI, STI, enteric fever and invasive salmonellosis in Africa.

It is already known that carbapenem resistance is mediated by transferable carbapenemase-encoding genes. These genes are already known from different research projects conducted in Europe, Asia and South America, whereas the African setting remains less explored and documented. Gram-negative bacteria, mainly *Enterobacteriaceae*, become resistant to carbapenems through three main mechanisms: enzyme production, efflux pumps and porin mutations. Three important groups of enzymes that are responsible for carbapenem resistance are: *KPC* (*Klebsiella pneumoniae* carbapenemase) (Ambler class A); MBLs (Metallo-β-Lactamases) (Ambler class B) and OXA-48-like (Ambler class D); and *blaIMP*, *blaVIM-1*, *blaSPM-1*, *blaNDM-1*, *blaOXA-23*, *blaOXA-24*, *blaOXA-58* and *blaKPC* resistance determinant genes reported from Africa.

In addition to the burden of resistance to front-line antibiotics (first- and second-line), ESBL production and carbapenems, *Vibrio cholerae* O1 serotype are also reported in this review. Cholera is responsible for around 4.3 million new cases and causes 21 000 to 143 000 deaths every year. Alterations in CTX phages and the pathogenicity islands contribute to the virulence of *V. cholerae* and are responsible for frequently reported cholera epidemics [287]. In most of the cases, *Vibrio cholerae* is associated with severe acute watery diarrhoea which remains the main distinctive symptom of cholera [288]. The *V. cholerae* serogroup O1 is the major cause of cholera outbreaks not only in Africa but also globally. The same serogroup was imported from Bangladesh, India, Iran and Iraq during the seventh pandemic that took place in the 1970s [289]. The evolved new variant of *Vibrio cholera* which is also more virulent was found to be associated with the CTX prophage rearrangements. This resistant *Vibrio Cholerae* strain is globally disseminated and constitutes a huge burden in low-resource settings such as Africa [290]. This mirrors the results of this review where most of the *V. cholerae* isolates reported in Africa belong to the *V. cholerae* O1 serogroup. This review also highlighted the carriage of two (*ctxB* and *tcpA*) out of three known biotype-specific genes (*ctxB*, *rstR*, *tcpA*) and one out of 13 known putative virulence genes (*ctxA*, *ctxB*, *zot*, *ace*, *tcpA*, *hlyA*, *stn*, *chxA*, *rtxA*, *ompU*, *toxR*, *mshA*, *TTSS*) of *V. cholerae* O1 [291]. Although there are still gap in timely reporting of data, Africa remains the main setting where cholera outbreaks and epidemics occur.

AMR data from Africa also indicate an increase of HIV drug resistance. In many African countries, tenofovir-containing regimens constitute the recommended first-line antiretroviral therapy (ART) and utilization of second-line treatment in these countries is still limited; a good example is South Africa. However, a considerable proportion of HIV drug resistance was reported in people living with HIV receiving tenofovir-containing first-line ART. The findings of this review highlight resistance to NNRTIs. Therefore, to meet the global target to end AIDS by 2030, NNRTIs should be replaced as first-line ART treatments in endemic settings such as Africa. In the same vein, dolutegravir is currently included in first-line regimens to treat HIV. As a matter of fact,

dolutegravir (DTG) in combination with an NRTI backbone is recommended as the preferred first-line regimen for people living with HIV and initiating ART, whereas DTG in combination with an optimized NRTI backbone may be recommended as a preferred second-line regimen for people living with HIV for whom non-DTG-based regimens are failing.

For TB, the first-line treatment tablets include isoniazid, rifampicin, pyrazinamide and ethambutol. For all retreatment cases (relapse, failure, and defaulter) a second line of treatment is administered: two months of R/H/Z/E/streptomycin, followed by one month of R/H/Z/E, and finally five months of R/H/E (eight months total treatment) [292]. However, in patients with confirmed rifampicin-susceptible and isoniazid-resistant tuberculosis, treatment with rifampicin, ethambutol, pyrazinamide and levofloxacin is recommended for a duration of six months. The burden of AMR in tuberculosis in Africa is growing and is largely driven by the considerable spread of MDR and extensively drug-resistant (XDR) mycobacterium tuberculosis strains. MDR-TB, which is defined as resistance to isoniazid and rifampicin, is frequently reported from African countries where HIV/AIDS remains endemic. This constitutes a major barrier to the WHO target of ending TB by 2035, since Africa remains the main source of new cases of TB. Therefore, urgent efforts and adoption of new tools for surveillance are required to confirm and report the true burden of AMR in tuberculosis in Africa.

The widespread use of antimalarial drugs has contributed significantly to the failure of the existing antimalarial drugs on the market, and this has hampered the achievement of the targets for eradication of malaria worldwide. Resistance to antimalarial drugs has been frequently reported since the 1950s and malaria has subsequently developed different mechanisms of resistance to successively developed drugs.

Malaria infection is now commonly treated with a combination of two drugs; artemisinin and piperaquine. However, resistance to antifolates, which are used to prevent malaria in some settings, remains widespread. Moreover, resistance to artemisinin-based combination therapies, the currently used standard treatment for malaria in Africa, has recently emerged. Resistance to artemisinin was reported from Rwanda for the first time in Africa [283]. This set a devastating scenario on the African continent where, in 2018, over 90% of the more than 400 000 deaths recorded from malaria were reported. Mutations in the *Plasmodium falciparum* multidrug-resistant gene (*pfmdr1*) was reported to alter the susceptibility of the parasite to artemisinin-based combination therapy [293].

The results of this review emphasize and recall the urgent need to improve surveillance programmes in each and every country of the WHO African Region to support antimicrobial stewardship.

4.2 Data limitations

The main limitations of this review include the exclusion of articles and reports published in languages other than English and French. For instance, there are several articles that are published in Spanish and Portuguese. Therefore, there could be articles from Spanish-speaking African countries (Equatorial Guinea) and Portuguese-speaking African countries (Angola, Cabo Verde, Guinea-Bissau, Mozambique and São Tomé and Príncipe) that were missed. Second, this review cannot guarantee the full representativeness of AST data since it only focused on articles with free access to their full content. In addition, this review reported AMR data only for medically important pathogens that are mostly reported in African laboratory settings. Furthermore, most African countries have poorly functioning laboratory, AMR surveillance and reporting systems. Therefore, their data were not accessible and were not included in this report.

There were very few reports from South Africa, which has a better functioning health and national AMR surveillance system than neighbouring countries. These data were not accessible for the search conducted for this review, and therefore larger AMR trends might have been missed. A further limitation relates to combining AMR results from different patient groups across different countries to compare the data. This approach might have levelled out peaks of resistance in different settings.

5. CONCLUSION AND RECOMMENDATIONS

5.1 Conclusion

This report presents an in-depth review of the most recent situation of AMR to the commonly prescribed antibiotics on the African continent. These AMR cases constitute a major and ongoing public health threat, and they are highlighted on the WHO list of critical-priority AMR bacteria for which new research, discovery, and development of new antibiotics are highly needed. In addition, resistance to first-line treatment regimens, MDR cases for HIV, TB and malaria are reported in Africa. The findings of this review will fill the gaps in AMR data for Africa; will help decision-makers and health care workers to develop more efficient preventive strategies as well as adequate policies for antibiotic stewardship and surveillance in line with the global action plan for AMR. More timely and effective surveillance studies and programmes for bacterial infections are required to deal with the current AMR threats presented in this report for the WHO African Region. This will result in a considerable positive impact on patients and reduce health care costs on the continent.

5.2 Recommendations

First, from the data extraction and analysis, it was observed that different panels of antibiotics, different AST methods were used without adhering to international recognised AST interpretation guidelines or standards. Thus, standardization of microbiological identification and AST methods is needed in diagnostic and research laboratories in the WHO African Region.

Second, considering the regularly reported lack of AMR data from Africa, accurate and sustainable surveillance for the emergence of AMR and sharing of data from Africa in the GLASS system should constitute high priorities. This will enable regional and international organizations such as WHO and other stakeholders to monitor the extent and evolution of the AMR problem on the continent. Finally, the different WHO consolidated lists of essential medicines should be successfully implemented or adapted based on the local AMR status.

REFERENCES

1. Irek EO, Amupitan AA, Obadare TO, Aboderin AO: **A systematic review of healthcare-associated infections in Africa: An antimicrobial resistance perspective.** *African journal of laboratory medicine* 2018, **7**(2):796.
2. Sefton AM: **Mechanisms of antimicrobial resistance: their clinical relevance in the new millennium.** *Drugs* 2002, **62**(4):557-566.
3. Munita JM, Arias CA: **Mechanisms of Antibiotic Resistance.** *Microbiology spectrum* 2016, **4**(2).
4. Ayukekpong JA, Ntemgwa M, Atabe AN: **The threat of antimicrobial resistance in developing countries: causes and control strategies.** *Antimicrobial resistance and infection control* 2017, **6**:47.
5. Opota O, Croxatto A, Prod'hom G, Greub G: **Blood culture-based diagnosis of bacteraemia: state of the art.** *Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases* 2015, **21**(4):313-322.
6. Ferguson JK, Joseph J, Kangapu S, Zoleveke H, Townell N, Duke T *et al* : **Quality microbiological diagnostics and antimicrobial susceptibility testing, an essential component of antimicrobial resistance surveillance and control efforts in Pacific island nations.** *Western Pacific surveillance and response journal : WPSAR* 2020, **11**(1):41-46.
7. Koeth LM, DiFranco-Fisher JM, McCurdy S: **A Reference Broth Microdilution Method for Dalbavancin In Vitro Susceptibility Testing of Bacteria that Grow Aerobically.** *Journal of visualized experiments : JoVE* 2015(103).
8. Abdel-Rahim MH, El-Badawy O, Hadiya S, Daef EA, Suh SJ, Boothe DM *et al*: **Patterns of Fluoroquinolone Resistance in Enterobacteriaceae Isolated from the Assiut University Hospitals, Egypt: A Comparative Study.** *Microbial drug resistance (Larchmont, NY)* 2019, **25**(4):509-519.
9. Abdelkareem MZ, Sayed M, Hassuna NA, Mahmoud MS, Abdelwahab SF: **Multi-drug-resistant Enterococcus faecalis among Egyptian patients with urinary tract infection.** *Journal of chemotherapy (Florence, Italy)* 2017, **29**(2):74-82.
10. Acheampong G, Owusu M, Owusu-Ofori A, Osei I, Sarpong N, Sylverken A *et al*: **Chromosomal and plasmid-mediated fluoroquinolone resistance in human *Salmonella enterica* infection in Ghana.** *BMC infectious diseases* 2019, **19**(1):898.
11. Agyepong N, Govinden U, Owusu-Ofori A, Amoako DG, Allam M, Janice J *et al*: **Genomic characterization of multidrug-resistant ESBL-producing *Klebsiella pneumoniae* isolated from a Ghanaian teaching hospital.** *International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases* 2019, **85**:117-123.

12. Akullian A, Montgomery JM, John-Stewart G, Miller SI, Hayden HS, Radey MC *et al*: **Multi-drug resistant non-typhoidal *Salmonella* associated with invasive disease in western Kenya.** *PLoS neglected tropical diseases* 2018, **12**(1):e0006156.
13. Al-Emran HM, Heisig A, Dekker D, Adu-Sarkodie Y, Cruz Espinoza LM, Panzner U *et al*: **Detection of a Novel *gyrB* Mutation Associated With Fluoroquinolone-Nonsusceptible *Salmonella enterica* serovar *Typhimurium* Isolated From a Bloodstream Infection in Ghana.** *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America* 2016, **62 Suppl 1**:S47-49.
14. Al-Emran HM, Eibach D, Krumkamp R, Ali M, Baker S, Biggs HM *et al*: **A Multicountry Molecular Analysis of *Salmonella enterica* Serovar *Typhi* With Reduced Susceptibility to Ciprofloxacin in Sub-Saharan Africa.** *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America* 2016, **62 Suppl 1**(Suppl 1):S42-46.
15. Aladarose BE, Said HS, Abdelmegeed ES: **Incidence of Virulence Determinants Among Enterococcal Clinical Isolates in Egypt and Its Association with Biofilm Formation.** *Microbial drug resistance (Larchmont, NY)* 2019, **25**(6):880-889.
16. Aldrich C, Hartman H, Feasey N, Chattaway MA, Dekker D, Al-Emran HM *et al*: **Emergence of phylogenetically diverse and fluoroquinolone resistant *Salmonella Enteritidis* as a cause of invasive nontyphoidal *Salmonella* disease in Ghana.** *PLoS neglected tropical diseases* 2019, **13**(6):e0007485.
17. Bachir M, Allem R, Benejat L, Tifrit A, Medjekane M, Drici AE *et al*: **Molecular detection of mutations involved in *Helicobacter pylori* antibiotic resistance in Algeria.** *The Journal of antimicrobial chemotherapy* 2018, **73**(8):2034-2038.
18. Wassef M, Abdelhaleim M, Ghaith D, El-Mahdy Y: **Emerging New Delhi metallo-β-lactamase-1-type-producing Gram-negative bacteria isolated from Cairo University Pediatric Hospital, Cairo, Egypt.** *Journal of global antimicrobial resistance* 2016, **7**:84-87.
19. Vasaikar S, Obi L, Morobe I, Bisi-Johnson M: **Molecular Characteristics and Antibiotic Resistance Profiles of *Klebsiella* Isolates in Mthatha, Eastern Cape Province, South Africa.** *International journal of microbiology* 2017, **2017**:8486742.
20. Phoba MF, Barbé B, Lunguya O, Masendu L, Lulengwa D, Dougan G *et al*: ***Salmonella enterica* serovar *Typhi* Producing CTX-M-15 Extended Spectrum β-Lactamase in the Democratic Republic of the Congo.** *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America* 2017, **65**(7):1229-1231.
21. Osei Sekyere J, Amoako DG: **Genomic and phenotypic characterisation of fluoroquinolone resistance mechanisms in Enterobacteriaceae in Durban, South Africa.** *PloS one* 2017, **12**(6):e0178888.
22. Clinical and Laboratory Standards Institute (CLSI): **Performance Standards for Antimicrobial Susceptibility Testing; 28th ed, CLSI supplement M100.** Wayne, PA. Clinical and Laboratory Standards Institute. 2018.
23. European Committee on Antimicrobial Susceptibility Testing (EUCAST): **Breakpoint tables for interpretation of MICs and zone diameters Version 8.0.** 2018.

24. Comité de l'Antibiogramme de la Société Française de Microbiologie (CASM): **Comité de l'Antibiogramme de la Société Française de Microbiologie report 2003. International journal of antimicrobial agents** 2003, **21**(4):364-391.
25. British Society for Antimicrobial Chemotherapy (BSAC) BSfac: **Antimicrobial stewardship: from principles to practice** BSAC 2021.
26. Tadesse BT, Ashley EA, Ongarello S, Havumaki J, Wijegoonewardena M, González IJ *et al*: **Antimicrobial resistance in Africa: a systematic review.** *BMC infectious diseases* 2017, **17**(1):616.
27. Leopold SJ, van Leth F, Tarekegn H, Schultsz C: **Antimicrobial drug resistance among clinically relevant bacterial isolates in sub-Saharan Africa: a systematic review.** *The Journal of antimicrobial chemotherapy* 2014, **69**(9):2337-2353.
28. Le Doare K, Bielicki J, Heath PT, Sharland M: **Systematic Review of Antibiotic Resistance Rates Among Gram-Negative Bacteria in Children With Sepsis in Resource-Limited Countries.** *Journal of the Pediatric Infectious Diseases Society* 2015, **4**(1):11-20.
29. Knight GM, Glover RE, McQuaid CF, Olaru ID, Gallandat K, Leclerc QJ *et al*: **Antimicrobial resistance and COVID-19: Intersections and implications.** *eLife* 2021, **10**.
30. Ombelet S, Ronat JB, Walsh T, Yansouni CP, Cox J, Vlieghe E *et al*: **Clinical bacteriology in low-resource settings: today's solutions.** *The Lancet Infectious diseases* 2018, **18**(8):e248-e258.
31. World Health Organization (WHO): **Global Antimicrobial Resistance Surveillance System (GLASS): Whole-genome sequencing for surveillance of antimicrobial resistance WHO report 2020.**
32. Abana D, Gyamfi E, Dogbe M, Opoku G, Opare D, Boateng G *et al*: **Investigating the virulence genes and antibiotic susceptibility patterns of Vibrio cholerae O1 in environmental and clinical isolates in Accra, Ghana.** *BMC infectious diseases* 2019, **19**(1):76.
33. Abayneh M, Tesfaw G, Abdissa A: **Isolation of Extended-Spectrum β-lactamase- (ESBL-) Producing Escherichia coli and Klebsiella pneumoniae from Patients with Community-Onset Urinary Tract Infections in Jimma University Specialized Hospital, Southwest Ethiopia.** *The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale* 2018, **2018**:4846159.
34. Abaza AF, Mohamed ON, El-Fiky FK, Ahmed KA: **Nasal carriage of methicillin-resistant Staphylococcus aureus and the effect of tea extracts on isolates.** *The Journal of the Egyptian Public Health Association* 2016, **91**(3):135-143.
35. Abaza AF, El Shazly SA, Selim HSA, Aly GSA: **Metallo-Beta-Lactamase Producing Pseudomonas aeruginosa in a Healthcare Setting in Alexandria, Egypt.** *Polish journal of microbiology* 2017, **66**(3):297-308.
36. Abbas HA, El-Ganiny AM, Kamel HA: **Phenotypic and genotypic detection of antibiotic resistance of Pseudomonas aeruginosa isolated from urinary tract infections.** *African health sciences* 2018, **18**(1):11-21.
37. Abd-Elmonsef MME, Elsharawy D, Abd-Elsalam AS: **Mechanical ventilator as a major cause of infection and drug resistance in intensive care unit.** *Environmental science and pollution research international* 2018, **25**(31):30787-30792.
38. Abda EM, Adugna Z, Assefa A: **Elevated Level of Imipenem-Resistant Gram-Negative Bacteria Isolated from Patients Attending Health Centers in North Gondar, Ethiopia.** *Infection and drug resistance* 2020, **13**:4509-4517.

39. Abdulall AK, Tawfick MM, El Manakhly AR, El Kholy A: **Carbapenem-resistant Gram-negative bacteria associated with catheter-related bloodstream infections in three intensive care units in Egypt.** *European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology* 2018, **37**(9):1647-1652.
40. Abera B, Kibret M, Mulu W: **Extended-Spectrum beta (β)-Lactamases and Antibiogram in Enterobacteriaceae from Clinical and Drinking Water Sources from Bahir Dar City, Ethiopia.** *Plos one* 2016, **11**(11):e0166519.
41. Abie S, Tiruneh M, Abebe W: **Methicillin-resistant *Staphylococcus aureus* nasal carriage among janitors working in hospital and non-hospital areas: a comparative cross-sectional study.** *Annals of clinical microbiology and antimicrobials* 2020, **19**(1):47.
42. Abotsi RE, Govinden U, Moodley K, Essack S: **Fluoroquinolone, Macrolide, and Ketolide Resistance in *Haemophilus parainfluenzae* from South Africa.** *Microbial drug resistance (Larchmont, NY)* 2017, **23**(6):667-673.
43. Abouelfetouh A, Torky AS, Aboulmagd E: **Phenotypic and genotypic characterization of carbapenem-resistant *Acinetobacter baumannii* isolates from Egypt.** *Antimicrobial resistance and infection control* 2019, **8**:185.
44. Achek R, Hotzel H, Cantekin Z, Nabi I, Hamdi TM, Neubauer H *et al*: **Emerging of antimicrobial resistance in staphylococci isolated from clinical and food samples in Algeria.** *BMC research notes* 2018, **11**(1):663.
45. Adane A, Belay G, Tamirat KS: **Microbiological Profile and Drug-Resistance Pattern of Pathogens Among Patients Who Visited the University of Gondar Comprehensive Specialized Hospital, Ethiopia.** *Infection and drug resistance* 2020, **13**:4449-4458.
46. Agyepong N, Govinden U, Owusu-Ofori A, Essack SY: **Multidrug-resistant gram-negative bacterial infections in a teaching hospital in Ghana.** *Antimicrobial resistance and infection control* 2018, **7**:37.
47. Akinniyi AM AA, Kolawole A, Giwa F and Randawa A **The prevalence of asymptomatic Group B streptococcal infection and antimicrobial sensitivity pattern among parturients at Ahmadu Bello University Teaching Hospital, Zaria, Nigeria.** *Tropical Journal of Obstetrics and Gynaecology* 2017, **33**(3).
48. Aku FY, Akweongo P, Nyarko K, Sackey S, Wurapa F, Afari EA *et al*: **Bacteriological profile and antibiotic susceptibility pattern of common isolates of neonatal sepsis, Ho Municipality, Ghana-2016.** *Maternal health, neonatology and perinatology* 2018, **4**:2.
49. Alebachew G, Teka B, Endris M, Shiferaw Y, Tessema B: **Etiologic Agents of Bacterial Sepsis and Their Antibiotic Susceptibility Patterns among Patients Living with Human Immunodeficiency Virus at Gondar University Teaching Hospital, Northwest Ethiopia.** *BioMed research international* 2016, **2016**:5371875.
50. Alemayehu T, Mekasha A, Abebe T: **Nasal carriage rate and antibiotic susceptibility pattern of *Neisseria meningitidis* in healthy Ethiopian children and adolescents: A cross-sectional study.** *PloS one* 2017, **12**(10):e0187207.
51. Ali MM, Woldeamanuel Y, Asrat D, Fenta DA, Beall B, Schrag S *et al*: **Features of *Streptococcus agalactiae* strains recovered from pregnant women and newborns attending different hospitals in Ethiopia.** *BMC infectious diseases* 2020, **20**(1):848.

52. Ali S, Sewunet T, Sahlemariam Z, Kibru G: **Neisseria gonorrhoeae among suspects of sexually transmitted infection in Gambella hospital, Ethiopia: risk factors and drug resistance.** *BMC research notes* 2016, **9**(1):439.
53. Ameya G, Weldemedhin T, Tsalla T, Gebremeskel F: **Antimicrobial Susceptibility Pattern and Associated Factors of Pediatric Septicemia in Southern Ethiopia.** *Infection and drug resistance* 2020, **13**:3895-3905.
54. Ameya G, Tsalla T, Getu F, Getu E: **Antimicrobial susceptibility pattern, and associated factors of Salmonella and Shigella infections among under five children in Arba Minch, South Ethiopia.** *Annals of clinical microbiology and antimicrobials* 2018, **17**(1):1.
55. Ampaire L, Nduhura E, Wewedru I: **Phenotypic prevalence of extended spectrum beta-lactamases among enterobacteriaceae isolated at Mulago National Referral Hospital: Uganda.** *BMC research notes* 2017, **10**(1):448.
56. Anteneh Amsalu ZG, Demissie Asegu and Setegn Eshetie: **Antimicrobial resistance pattern of bacterial isolates from different clinical specimens in Southern Ethiopia: A three year retrospective study.** *African Journal of Bacteriology Research* 2017, **9**(1).
57. Andrew B, Kagirita A, Bazira J: **Prevalence of Extended-Spectrum Beta-Lactamases-Producing Microorganisms in Patients Admitted at KRRH, Southwestern Uganda.** *International journal of microbiology* 2017, **2017**:3183076.
58. Antri K, Akkou M, Bouchiat C, Bes M, Martins-Simoes P, Dauwalder O *et al*: **High levels of Staphylococcus aureus and MRSA carriage in healthy population of Algiers revealed by additional enrichment and multisite screening.** *European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology* 2018, **37**(8):1521-1529.
59. Apandi OE, Oduor OC, Gye BK, Kipkoech MK: **HIGH PREVALENCE OF MULTI-DRUG RESISTANT KLEBSIELLA PNEUMONIAE IN A TERTIARY TEACHING HOSPITAL IN WESTERN KENYA.** *African journal of infectious diseases* 2016, **10**(2):89-95.
60. Arega B, Woldeamanuel Y, Adane K, Sherif AA, Asrat D: **Microbial spectrum and drug-resistance profile of isolates causing bloodstream infections in febrile cancer patients at a referral hospital in Addis Ababa, Ethiopia.** *Infection and drug resistance* 2018, **11**:1511-1519.
61. Adediwura O Arowosegbe DAO, Iyabode O Dedeke, Olufunke B, Akingbade SaOA: **Neonatal sepsis in a Nigerian Tertiary Hospital: Clinical features, clinical outcome, aetiology and antibiotic susceptibility pattern.** *Southern African Journal of Infectious Diseases* 2017, **1**(1).
62. Getachew Seyoum Asres MHLGMW: **Prevalence of multidrug resistant Bacteria in postoperative wound infections at Tikur Anbessa specialized hospital, Addis Ababa, Ethiopia.** *Archives of medicine* 2017, **9**(4).
63. Assefa S, Desta K, Lema T: **Group B streptococci vaginal colonization and drug susceptibility pattern among pregnant women attending in selected public antenatal care centers in Addis Ababa, Ethiopia.** *BMC pregnancy and childbirth* 2018, **18**(1):135.
64. Assegu Fenta D, Lemma K, Tadele H, Tadesse BT, Derese B: **Antimicrobial sensitivity profile and bacterial isolates among suspected pyogenic meningitis patients attending at Hawassa University Hospital: Cross-sectional study.** *BMC microbiology* 2020, **20**(1):125.

65. Attram N, Agbodzi B, Dela H, Behene E, Nyarko EO, Kyei NNA *et al*: **Antimicrobial resistance (AMR) and molecular characterization of *Neisseria gonorrhoeae* in Ghana, 2012-2015.** *PloS one* 2019, **14**(10):e0223598.
66. Awad HA, Mohamed MH, Badran NF, Mohsen M, Abd-Elrhman AS: **Multidrug-resistant organisms in neonatal sepsis in two tertiary neonatal ICUs, Egypt.** *The Journal of the Egyptian Public Health Association* 2016, **91**(1):31-38.
67. Ayelign B, Abebe B, Shibeshi A, Meshesha S, Shibabaw T, Addis Z *et al*: **Bacterial isolates and their antimicrobial susceptibility patterns among pediatric patients with urinary tract infections.** *Turkish journal of urology* 2018, **44**(1):62-69.
68. Ayoyi AO, Kikuvi G, Bii C, Kariuki S: **Prevalence, aetiology and antibiotic sensitivity profile of asymptomatic bacteriuria isolates from pregnant women in selected antenatal clinic from Nairobi, Kenya.** *The Pan African medical journal* 2017, **26**:41.
69. Azzab MM, El-Sokkary RH, Tawfeek MM, Gebriel MG: **Multidrug-resistant bacteria among patients with ventilator-associated pneumonia in an emergency intensive care unit, Egypt.** *Eastern Mediterranean health journal = La revue de sante de la Mediterranee orientale = al-Majallah al-sihhiyah li-sharq al-mutawassit* 2017, **22**(12):894-903.
70. Bediako-Bowan AAA, Kurtzhals JAL, Mølbak K, Labi AK, Owusu E, Newman MJ: **High rates of multi-drug resistant gram-negative organisms associated with surgical site infections in a teaching hospital in Ghana.** *BMC infectious diseases* 2020, **20**(1):890.
71. Belete Y, Asrat D, Woldeamanuel Y, Yihenew G, Gize A: **Bacterial Profile And Antibiotic Susceptibility Pattern Of Urinary Tract Infection Among Children Attending Felege Hiwot Referral Hospital, Bahir Dar, Northwest Ethiopia.** *Infection and drug resistance* 2019, **12**:3575-3583.
72. Belyhun Y, Moges F, Endris M, Asmare B, Amare B, Bekele D *et al*: **Ocular bacterial infections and antibiotic resistance patterns in patients attending Gondar Teaching Hospital, Northwest Ethiopia.** *BMC research notes* 2018, **11**(1):597.
73. Benamrouche N, Lafer O, Benmahdi L, Benslimani A, Amhis W, Ammari H *et al*: **Phenotypic and genotypic characterization of multidrug-resistant *Acinetobacter baumannii* isolated in Algerian hospitals.** *Journal of infection in developing countries* 2020, **14**(12):1395-1401.
74. Beyene D, Bitew A, Fantew S, Mihret A, Evans M: **Multidrug-resistant profile and prevalence of extended spectrum β -lactamase and carbapenemase production in fermentative Gram-negative bacilli recovered from patients and specimens referred to National Reference Laboratory, Addis Ababa, Ethiopia.** *PloS one* 2019, **14**(9):e0222911.
75. Birindwa AM, Emgård M, Nordén R, Samuelsson E, Geravandi S, Gonzales-Siles L *et al*: **High rate of antibiotic resistance among pneumococci carried by healthy children in the eastern part of the Democratic Republic of the Congo.** *BMC pediatrics* 2018, **18**(1):361.
76. Biset S, Moges F, Endalamaw D, Eshetie S: **Multi-drug resistant and extended-spectrum β -lactamases producing bacterial uropathogens among pregnant women in Northwest Ethiopia.** *Annals of clinical microbiology and antimicrobials* 2020, **19**(1):25.
77. Bitew A, Tsige E: **High Prevalence of Multidrug-Resistant and Extended-Spectrum β -Lactamase-Producing Enterobacteriaceae: A Cross-Sectional Study at Arsho Advanced Medical Laboratory, Addis Ababa, Ethiopia.** *Journal of tropical medicine* 2020, **2020**:6167234.

78. Bitew A, Molalign T, Chanie M: **Species distribution and antibiotic susceptibility profile of bacterial uropathogens among patients complaining urinary tract infections.** *BMC infectious diseases* 2017, **17**(1):654.
79. Adane Bitew MAaiG: **Spectrum and Drug Susceptibility Profile of Bacteria Recovered from Patients with Wound Infection Referred to Arsho Advanced Medical Laboratory.** *Clinical Medicine research* 2018, **7**(1).
80. Bitew Kifilie A, Dagnew M, Tegenie B, Yeshitela B, Howe R, Abate E: **Bacterial Profile, Antibacterial Resistance Pattern, and Associated Factors from Women Attending Postnatal Health Service at University of Gondar Teaching Hospital, Northwest Ethiopia.** *International journal of microbiology* 2018, **2018**:3165391.
81. Bojang A, Camara B, Jagne Cox I, Oluwalana C, Lette K, Usuf E *et al*: **Long-term Impact of Oral Azithromycin Taken by Gambian Women During Labor on Prevalence and Antibiotic Susceptibility of Streptococcus pneumoniae and Staphylococcus aureus in Their Infants: Follow-up of a Randomized Clinical Trial.** *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America* 2018, **67**(8):1191-1197.
82. Bouihat N, Buruoa C, Benkirane A, Seddik H, Sentissi S, Al Bouzidi A *et al*: **Helicobacter pylori Primary Antibiotic Resistance in 2015 in Morocco: A Phenotypic and Genotypic Prospective and Multicenter Study.** *Microbial drug resistance (Larchmont, NY)* 2017, **23**(6):727-732.
83. Boutarfi Z, Rebiahi SA, Morghad T, Perez Pulido R, Grande Burgos MJ, Mahdi F *et al*: **Biocide tolerance and antibiotic resistance of Enterobacter spp. isolated from an Algerian hospital environment.** *Journal of global antimicrobial resistance* 2019, **18**:291-297.
84. Brander RL, Walson JL, John-Stewart GC, Naulikha JM, Ndonye J, Kipkemoi N *et al*: **Correlates of multi-drug non-susceptibility in enteric bacteria isolated from Kenyan children with acute diarrhea.** *PLoS neglected tropical diseases* 2017, **11**(10):e0005974.
85. Breurec S, Reynaud Y, Frank T, Farra A, Costilhes G, Weill FX *et al*: **Serotype distribution and antimicrobial resistance of human Salmonella enterica in Bangui, Central African Republic, from 2004 to 2013.** *PLoS neglected tropical diseases* 2019, **13**(12):e0007917.
86. Chiyangi H, Muma JB, Malama S, Manyahi J, Abade A, Kwenda G *et al*: **Identification and antimicrobial resistance patterns of bacterial enteropathogens from children aged 0-59 months at the University Teaching Hospital, Lusaka, Zambia: a prospective cross sectional study.** *BMC infectious diseases* 2017, **17**(1):117.
87. DeFrancesco AS, Tanih NF, Samie A, Guerrant RL, Bessong PO: **Antibiotic resistance patterns and beta-lactamase identification in Escherichia coli isolated from young children in rural Limpopo Province, South Africa: The MAL-ED cohort.** *South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde* 2017, **107**(3):205-214.
88. Dekker D, Wolters M, Mertens E, Boahen KG, Krumkamp R, Eibach D *et al*: **Antibiotic resistance and clonal diversity of invasive Staphylococcus aureus in the rural Ashanti Region, Ghana.** *BMC infectious diseases* 2016, **16**(1):720.
89. Deksissa T, Gebremedhin EZ: **A cross-sectional study of enteric fever among febrile patients at Ambo hospital: prevalence, risk factors, comparison of Widal test and stool culture and antimicrobials susceptibility pattern of isolates.** *BMC infectious diseases* 2019, **19**(1):288.

90. Dengo-Baloi LC, Semá-Baltazar CA, Manhique LV, Chitio JE, Inguane DL, Langa JP: **Antibiotics resistance in El Tor *Vibrio cholerae* 01 isolated during cholera outbreaks in Mozambique from 2012 to 2015.** *PLoS one* 2017, **12**(8):e0181496.
91. Derese B, Kedir H, Teklemariam Z, Weldegebreal F, Balakrishnan S: **Bacterial profile of urinary tract infection and antimicrobial susceptibility pattern among pregnant women attending at Antenatal Clinic in Dil Chora Referral Hospital, Dire Dawa, Eastern Ethiopia.** *Therapeutics and clinical risk management* 2016, **12**:251-260.
92. Dessie W, Mulugeta G, Fentaw S, Mihret A, Hassen M, Abebe E: **Pattern of Bacterial Pathogens and Their Susceptibility Isolated from Surgical Site Infections at Selected Referral Hospitals, Addis Ababa, Ethiopia.** *International journal of microbiology* 2016, **2016**:2418902.
93. Desta K, Woldeamanuel Y, Azazh A, Mohammed H, Desalegn D, Shimelis D *et al*: **High Gastrointestinal Colonization Rate with Extended-Spectrum β -Lactamase-Producing Enterobacteriaceae in Hospitalized Patients: Emergence of Carbapenemase-Producing *K. pneumoniae* in Ethiopia.** *PLoS one* 2016, **11**(8):e0161685.
94. Deyno S, Toma A, Worku M, Bekele M: **Antimicrobial resistance profile of *staphylococcus aureus* isolates isolated from ear discharges of patients at University of Hawassa comprehensive specialized hospital.** *BMC pharmacology & toxicology* 2017, **18**(1):35.
95. Deyno S, Fekadu S, Seyfe S: **Prevalence and antimicrobial resistance of coagulase negative staphylococci clinical isolates from Ethiopia: a meta-analysis.** *BMC microbiology* 2018, **18**(1):43.
96. Donkor GY, Dontoh E, Owusu-Ofori A: **A cross-sectional study on the prevalence of antibiotic use prior to laboratory tests at two Ghanaian hospitals.** *PLoS one* 2019, **14**(1):e0210716.
97. Duedu KO, Offei G, Codjoe FS, Donkor ES: **Multidrug Resistant Enteric Bacterial Pathogens in a Psychiatric Hospital in Ghana: Implications for Control of Nosocomial Infections.** *International journal of microbiology* 2017, **2017**:9509087.
98. Olivia Sochi Egbule ADEAUBO-U: **High Rate of Antibiotic Resistance in a Neonatal Intensive Care Unit of a University Hospital.** *British Microbiology Research journal* 2016, **15**(1).
99. Eguale T, Asrat D, Alemayehu H, Nana I, Gebreyes WA, Gunn JS *et al*: **Phenotypic and genotypic characterization of temporally related nontyphoidal *Salmonella* strains isolated from humans and food animals in central Ethiopia.** *Zoonoses and public health* 2018, **65**(7):766-776.
100. Uchenna Ekwochi ClaCDIO: **A 4-Year Prospective Study of Clinico-bacterial Profile and Antibiogram of Neonatal Bacterial Sepsis at a Tertiary Health Facility in a Resource-limited Setting.** *Journal of clinical neonatology* 2021, **7**(1).
101. El-Nawawy A, Ramadan MA, Antonios MA, Arafa SA, Hamza E: **Bacteriologic profile and susceptibility pattern of mechanically ventilated paediatric patients with pneumonia.** *Journal of global antimicrobial resistance* 2019, **18**:88-94.
102. El-Nawawy A, Ashraf GA, Antonios MAM, Meheissen MA, El-Alfy MMR: **Incidence of Multidrug-Resistant Organism Among Children Admitted to Pediatric Intensive Care Unit in a Developing Country.** *Microbial drug resistance (Larchmont, NY)* 2018, **24**(8):1198-1206.
103. Endaylalu K, Abera B, Mulu W: **Extended spectrum beta lactamase producing bacteria among outpatients with ear infection at FelegeHiwot Referral Hospital, North West Ethiopia.** *PLoS one* 2020, **15**(9):e0238891.

104. Eshetie S, Tarekegn F, Moges F, Amsalu A, Birhan W, Huruy K: **Methicillin resistant *Staphylococcus aureus* in Ethiopia: a meta-analysis.** *BMC infectious diseases* 2016, **16**(1):689.
105. Fenta A, Dagnew M, Eshetie S, Belachew T: **Bacterial profile, antibiotic susceptibility pattern and associated risk factors of urinary tract infection among clinically suspected children attending at Felege-Hiwot comprehensive and specialized hospital, Northwest Ethiopia. A prospective study.** *BMC infectious diseases* 2020, **20**(1):673.
106. Fentie A, Wondimeneh Y, Balcha A, Amsalu A, Adankie BT: **Bacterial profile, antibiotic resistance pattern and associated factors among cancer patients at University of Gondar Hospital, Northwest Ethiopia.** *Infection and drug resistance* 2018, **11**:2169-2178.
107. Garoy EY, Gebreab YB, Achila OO, Tekeste DG, Kesete R, Ghirmay R, et al: **Methicillin-Resistant *Staphylococcus aureus* (MRSA): Prevalence and antimicrobial Sensitivity Pattern among Patients- A Multicenter Study in Asmara, Eritrea.** *The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale* 2019, **2019**:8321834.
108. Gashaw M, Berhane M, Bekele S, Kibru G, Teshager L, Yilma Y et al: **Emergence of high drug resistant bacterial isolates from patients with health care associated infections at Jimma University medical center: a cross sectional study.** *Antimicrobial resistance and infection control* 2018, **7**:138.
109. Gashe F, Mulisa E, Mekonnen M, Zeleke G: **Antimicrobial Resistance Profile of Different Clinical Isolates against Third-Generation Cephalosporins.** *Journal of pharmaceutics* 2018, **2018**:5070742.
110. Gebre T, Tadesse M, Aragaw D, Feye D, Beyene HB, Seyoum D et al: **Nasopharyngeal Carriage and Antimicrobial Susceptibility Patterns of *Streptococcus pneumoniae* among Children under Five in Southwest Ethiopia.** *Children (Basel, Switzerland)* 2017, **4**(4).
111. Gebreegziabher G, Asrat D, Y WA, Hagos T: **Isolation and Antimicrobial Susceptibility Profile of *Shigella* and *Salmonella* Species from Children with Acute Diarrhoea in Mekelle Hospital and Semen Health Center, Ethiopia.** *Ethiopian journal of health sciences* 2018, **28**(2):197-206.
112. Gitau W, Masika M, Musyoki M, Museve B, Mutwiri T: **Antimicrobial susceptibility pattern of *Staphylococcus aureus* isolates from clinical specimens at Kenyatta National Hospital.** *BMC research notes* 2018, **11**(1):226.
113. Gizachew M, Tiruneh M, Moges F, Adefris M, Tigabu Z, Tessema B: **Newborn colonization and antibiotic susceptibility patterns of *Streptococcus agalactiae* at the University of Gondar Referral Hospital, Northwest Ethiopia.** *BMC pediatrics* 2018, **18**(1):378.
114. Gizachew M, Tiruneh M, Moges F, Adefris M, Tigabu Z, Tessema B: ***Streptococcus agalactiae* from Ethiopian pregnant women; prevalence, associated factors and antimicrobial resistance: alarming for prophylaxis.** *Annals of clinical microbiology and antimicrobials* 2019, **18**(1):3.
115. Gorems K, Beyene G, Berhane M, Mekonnen Z: **Antimicrobial susceptibility patterns of bacteria isolated from patients with ear discharge in Jimma Town, Southwest, Ethiopia.** *BMC ear, nose, and throat disorders* 2018, **18**:17.
116. Hailu D, Mekonnen D, Derbie A, Mulu W, Abera B: **Pathogenic bacteria profile and antimicrobial susceptibility patterns of ear infection at Bahir Dar Regional Health Research Laboratory Center, Ethiopia.** *SpringerPlus* 2016, **5**:466.

117. Han KS, Gustavo L, Rajkumar VC, Swe Swe-Han K: **Antimicrobial stewardship approach: Prevalence of antimicrobial resistant bacteria at a regional hospital in South Africa.** *Journal of infection in developing countries* 2019, **13**(8):748-752.
118. Hope D, Ampaire L, Oyet C, Muwanguzi E, Twizerimana H, Apecu RO: **Antimicrobial resistance in pathogenic aerobic bacteria causing surgical site infections in Mbarara regional referral hospital, Southwestern Uganda.** *Scientific reports* 2019, **9**(1):17299.
119. Iliyasu G, Mohammad FD, Habib AG: **COMMUNITY ACQUIRED PNEUMOCOCCAL PNEUMONIA IN NORTHWESTERN NIGERIA: EPIDEMIOLOGY, ANTIMICROBIAL RESISTANCE AND OUTCOME.** *African journal of infectious diseases* 2018, **12**(1):15-19.
120. Iramiot JS, Rwego IB, Kansiime C, Asiimwe BB: **Epidemiology and antibiotic susceptibility of Vibrio cholerae associated with the 2017 outbreak in Kasese district, Uganda.** *BMC public health* 2019, **19**(1):1405.
121. Iroh Tam PY, Musicha P, Kawaza K, Cornick J, Denis B, Freyne B *et al*: **Emerging Resistance to Empiric Antimicrobial Regimens for Pediatric Bloodstream Infections in Malawi (1998-2017).** *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America* 2019, **69**(1):61-68.
122. Ingle DJ, Levine MM, Kotloff KL, Holt KE, Robins-Browne RM: **Dynamics of antimicrobial resistance in intestinal Escherichia coli from children in community settings in South Asia and sub-Saharan Africa.** *Nature microbiology* 2018, **3**(9):1063-1073.
123. Janssen H, Janssen I, Cooper P, Kainyah C, Pellio T, Quintel M *et al*: **Antimicrobial-Resistant Bacteria in Infected Wounds, Ghana, 2014(1).** *Emerging infectious diseases* 2018, **24**(5):916-919.
124. Kabwe M, Tembo J, Chilukutu L, Chilufya M, Ngulube F, Lukwesa C *et al*: **Etiology, Antibiotic Resistance and Risk Factors for Neonatal Sepsis in a Large Referral Center in Zambia.** *The Pediatric infectious disease journal* 2016, **35**(7):e191-198.
125. Kamel NA, El-Tayeb WN, El-Ansary MR, Mansour MT, Aboshanab KM: **Phenotypic screening and molecular characterization of carbapenemase-producing Gram-negative bacilli recovered from febrile neutropenic pediatric cancer patients in Egypt.** *PloS one* 2018, **13**(8):e0202119.
126. Akosua B, Karikari KO-D, Enoch H, Frimpong and Karen A. Krogfelt: **Antibiotic Resistance in Campylobacter Isolated from Patients with Gastroenteritis in a Teaching Hospital in Ghana.** *Open Journal of medical microbiology* 2017, **7**(1).
127. Kashosi TM, Muhandule AB, Mwenebitu DL, Mihuhi N, Mutendela JK, Mubagwa K: **[Antibiotic resistance of Salmonella spp strains isolated from blood cultures in Bukavu, Democratic Republic of the Congo].** *The Pan African medical journal* 2018, **29**:42.
128. Kateete DP, Nakanjako R, Namugenyi J, Erume J, Joloba ML, Najjuka CF: **Carbapenem resistant Pseudomonas aeruginosa and Acinetobacter baumannii at Mulago Hospital in Kampala, Uganda (2007-2009).** *SpringerPlus* 2016, **5**(1):1308.
129. Kazimoto T, Abdulla S, Bategereza L, Juma O, Mhimbira F, Weisser M *et al*: **Causative agents and antimicrobial resistance patterns of human skin and soft tissue infections in Bagamoyo, Tanzania.** *Acta tropica* 2018, **186**:102-106.
130. Keddy KH, Musekiwa A, Sooka A, Karstaedt A, Nana T, Seetharam S, Nchabaleng M *et al*: **Clinical and microbiological features of invasive nontyphoidal Salmonella associated with HIV-infected patients, Gauteng Province, South Africa.** *Medicine* 2017, **96**(13):e6448.

131. Kemeze S, Moudze B, Chiabi A, Eposse C, Kaya A, Mbangue M *et al*: **Clinical and bacteriological profile of neonatal bacterial infection at Laquintinie Hospital, Douala (Cameroon)**. *The Pan African medical journal* 2016, **23**:97.
132. Kengne M, Fotie HBN, Nwobegahay JM, Achiangia PN, Tamoufe U, Goon DT *et al*: **Antibiotic sensitivity profile of *Staphylococcus aureus* isolated from HIV/AIDS patients presenting with pyoderma, at the Yaounde Central Hospital, Cameroon**. *The Pan African medical journal* 2020, **37**:185.
133. Kengne M, Fotsing O, Ndomgue T, Nwobegahay JM: **Antibiotic susceptibility patterns of *Staphylococcus aureus* strains isolated at the Yaounde Central Hospital, Cameroon: a retrospective study**. *The Pan African medical journal* 2019, **32**:103.
134. Kengne M, Lebogo MBB, Nwobegahay JM, Ondigui BE: **Antibiotics susceptibility pattern of *Streptococcus pneumoniae* isolated from sputum cultures of human immunodeficiency virus infected patients in Yaoundé, Cameroon**. *The Pan African medical journal* 2018, **31**:16.
135. Kengne M, Dounia AT, Nwobegahay JM: **Bacteriological profile and antimicrobial susceptibility patterns of urine culture isolates from patients in Ndjamenia, Chad**. *The Pan African medical journal* 2017, **28**:258.
136. Khairalla AS, Wasfi R, Ashour HM: **Carriage frequency, phenotypic, and genotypic characteristics of methicillin-resistant *Staphylococcus aureus* isolated from dental health-care personnel, patients, and environment**. *Scientific reports* 2017, **7**(1):7390.
137. Khairy RMM, Mahmoud MS, Shady RR, Esmail MAM: **Multidrug-resistant *Klebsiella pneumoniae* in hospital-acquired infections: Concomitant analysis of antimicrobial resistant strains**. *International journal of clinical practice* 2020, **74**(4):e13463.
138. Khalifa HO, Soliman AM, Ahmed AM, Shimamoto T, Nariya H, Matsumoto T *et al*: **High Prevalence of Antimicrobial Resistance in Gram-Negative Bacteria Isolated from Clinical Settings in Egypt: Recalling for Judicious Use of Conventional Antimicrobials in Developing Nations**. *Microbial drug resistance (Larchmont, NY)* 2019, **25**(3):371-385.
139. Khalifa HO, Soliman AM, Ahmed AM, Shimamoto T, Hara T, Ikeda M *et al*: **High Carbapenem Resistance in Clinical Gram-Negative Pathogens Isolated in Egypt**. *Microbial drug resistance (Larchmont, NY)* 2017, **23**(7):838-844.
140. Kieffer N, Nordmann P, Aires-de-Sousa M, Poirel L: **High Prevalence of Carbapenemase-Producing Enterobacteriaceae among Hospitalized Children in Luanda, Angola**. *Antimicrobial agents and chemotherapy* 2016, **60**(10):6189-6192.
141. Konaté A, Dembélé R, Guessennd NK, Kouadio FK, Kouadio IK, Ouattara MB *et al*: **Epidemiology and Antibiotic Resistance Phenotypes of Diarrheagenic *Escherichia coli* Responsible for Infantile Gastroenteritis in Ouagadougou, Burkina Faso**. *European journal of microbiology & immunology* 2017, **7**(3):168-175.
142. KPODA D.S GN, SOMDA N.S, AJAYI A., BONKOUNGOU J.I, KONAN F., OUATTARA M.B *et al*: **Antimicrobial susceptibility of extended-spectrum beta-lactamase producing Enterobacteriaceae causing urinary tract infections in Ouagadougou, Burkina Faso** *African journal of clinical and experimental microbiology* 2017, **18**(3).

143. Kumburu HH, Sonda T, Mmbaga BT, Alifrangis M, Lund O, Kibiki G *et al*: **Patterns of infections, aetiological agents and antimicrobial resistance at a tertiary care hospital in northern Tanzania.** *Tropical medicine & international health : TM & IH* 2017, **22**(4):454-464.
144. Kumwenda GP, Sugawara Y, Abe R, Akeda Y, Kasambara W, Chizani K *et al*: **First Identification and genomic characterization of multidrug-resistant carbapenemase-producing Enterobacteriaceae clinical isolates in Malawi, Africa.** *Journal of medical microbiology* 2019, **68**(12):1707-1715.
145. Kyany'a C, Nyasinga J, Matano D, Oundo V, Wacira S, Sang W *et al*: **Phenotypic and genotypic characterization of clinical *Staphylococcus aureus* isolates from Kenya.** *BMC microbiology* 2019, **19**(1):245.
146. Labi AK, Obeng-Nkrumah N, Sunkwa-Mills G, Bediako-Bowan A, Akufo C, Bjerrum S *et al*: **Antibiotic prescribing in paediatric inpatients in Ghana: a multi-centre point prevalence survey.** *BMC pediatrics* 2018, **18**(1):391.
147. Legese MH, Weldearegay GM, Asrat D: **Extended-spectrum beta-lactamase- and carbapenemase-producing Enterobacteriaceae among Ethiopian children.** *Infection and drug resistance* 2017, **10**:27-34.
148. Legese H, Kahsay AG, Kahsay A, Araya T, Adhanom G, Muthupandian S *et al*: **Nasal carriage, risk factors and antimicrobial susceptibility pattern of methicillin resistant *Staphylococcus aureus* among healthcare workers in Adigrat and Wukro hospitals, Tigray, Northern Ethiopia.** *BMC research notes* 2018, **11**(1):250.
149. Maïga A, Dicko OA, Tchougoune LM, Fofana DB, Coulibaly DM, Maïga, II: **[High prevalence of methicillin-resistant *Staphylococcus aureus* strains in the Point G teaching hospital in Bamako, Mali].** *Le Mali medical* 2017, **32**(3):1-8.
150. Maina D, Omuse G, Revathi G, Adam RD: **Spectrum of Microbial Diseases and Resistance Patterns at a Private Teaching Hospital in Kenya: Implications for Clinical Practice.** *PloS one* 2016, **11**(1):e0147659.
151. Mama M, Alemu G: **Prevalence, antimicrobial susceptibility patterns and associated risk factors of *Shigella* and *Salmonella* among food handlers in Arba Minch University, South Ethiopia.** *BMC infectious diseases* 2016, **16**(1):686.
152. Mama M, Aklilu A, Misgna K, Tadesse M, Alemayehu E: **Methicillin- and Inducible Clindamycin-Resistant *Staphylococcus aureus* among Patients with Wound Infection Attending Arba Minch Hospital, South Ethiopia.** *International journal of microbiology* 2019, **2019**:2965490.
153. Mamuye Y: **Antibiotic Resistance Patterns of Common Gram-negative Uropathogens in St. Paul's Hospital Millennium Medical College.** *Ethiopian journal of health sciences* 2016, **26**(2):93-100.
154. Manilal A, Shewangizaw M, Mama M, Gezmu T, Merdekios B: **Methicillin-resistant *Staphylococcus aureus* colonization in HIV patients of Arba Minch province, Ethiopia: Carriage rates, antibiotic resistance, and biofilm formation.** *Acta microbiologica et immunologica Hungarica* 2019, **66**(4):469-483.
155. Marami D, Hailu K, Tolera M: **Prevalence and antimicrobial susceptibility pattern of *Salmonella* and *Shigella* species among asymptomatic food handlers working in Haramaya University cafeterias, Eastern Ethiopia.** *BMC research notes* 2018, **11**(1):74.

156. Marbou WJT, Kuete V: **Bacterial resistance and immunological profiles in HIV-infected and non-infected patients at Mbouda AD LUCEM Hospital in Cameroon.** *Journal of infection and public health* 2017, **10**(3):269-276.
157. Masaisa F, Kayigi E, Seni J, Bwanga F, Muvunyi CM: **Antibiotic Resistance Patterns and Molecular Characterization of Methicillin-Resistant *Staphylococcus aureus* in Clinical Settings in Rwanda.** *The American journal of tropical medicine and hygiene* 2018, **99**(5):1239-1245.
158. Mathlouthi N, Al-Bayssari C, El Salabi A, Bakour S, Ben Gwierif S, Zorgani AA *et al*: **Carbapenemases and extended-spectrum β -lactamases producing Enterobacteriaceae isolated from Tunisian and Libyan hospitals.** *Journal of infection in developing countries* 2016, **10**(7):718-727.
159. Medboua-Benbalagh C, Touati A, Kermas R, Gharout-Sait A, Brasme L, Mezhoud H *et al*: **Fecal Carriage of Extended-Spectrum β -Lactamase-Producing Enterobacteriaceae Strains Is Associated with Worse Outcome in Patients Hospitalized in the Pediatric Oncology Unit of Beni-Messous Hospital in Algiers, Algeria.** *Microbial drug resistance (Larchmont, NY)* 2017, **23**(6):757-763.
160. Mekonnen GK, Mengistie B, Sahilu G, Kloos H, Mulat W: **Etiologies of diarrhea and drug susceptibility patterns of bacterial isolates among under-five year children in refugee camps in Gambella Region, Ethiopia: a case control study.** *BMC infectious diseases* 2019, **19**(1):1008.
161. Mengist A, Kannan H, Abdissa A: **Prevalence and antimicrobial susceptibility pattern of anorectal and vaginal group B Streptococci isolates among pregnant women in Jimma, Ethiopia.** *BMC research notes* 2016, **9**:351.
162. Mengist HM, Zewdie O, Belew A, Dabsu R: **Prevalence and drug susceptibility pattern of group B Streptococci (GBS) among pregnant women attending antenatal care (ANC) in Nekemte Referral Hospital (NRH), Nekemte, Ethiopia.** *BMC research notes* 2017, **10**(1):388.
163. Mitiku H, Weldegebreal F, Marami D, Teklemariam Z: **Nontyphoidal *Salmonella* bacteremia in antiretroviral therapy-naïve HIV-infected individuals at three public hospitals in Eastern Ethiopia: prevalence, antimicrobial susceptibility patterns, and associated factors.** *HIV/AIDS (Auckland, NZ)* 2019, **11**:23-29.
164. Moges F, Eshetie S, Abebe W, Mekonnen F, Dagnew M, Endale A *et al*: **High prevalence of extended-spectrum beta-lactamase-producing Gram-negative pathogens from patients attending Felege Hiwot Comprehensive Specialized Hospital, Bahir Dar, Amhara region.** *PloS one* 2019, **14**(4):e0215177.
165. Mohammed A, Seid ME, Gebrecherkos T, Tiruneh M, Moges F: **Bacterial Isolates and Their Antimicrobial Susceptibility Patterns of Wound Infections among Inpatients and Outpatients Attending the University of Gondar Referral Hospital, Northwest Ethiopia.** *International journal of microbiology* 2017, **2017**:8953829.
166. Moraleda C, Benmessaoud R, Esteban J, López Y, Alami H, Barkat A *et al*: **Prevalence, antimicrobial resistance and serotype distribution of group B streptococcus isolated among pregnant women and newborns in Rabat, Morocco.** *Journal of medical microbiology* 2018, **67**(5):652-661.
167. Moremi N, Claus H, Mshana SE: **Antimicrobial resistance pattern: a report of microbiological cultures at a tertiary hospital in Tanzania.** *BMC infectious diseases* 2016, **16**(1):756.

168. Motbainor H, Beredet F, Mulu W: **Multi-drug resistance of blood stream, urinary tract and surgical site nosocomial infections of *Acinetobacter baumannii* and *Pseudomonas aeruginosa* among patients hospitalized at Felegehiwot referral hospital, Northwest Ethiopia: a cross-sectional study.** *BMC infectious diseases* 2020, **20**(1):92.
169. Mpinda-Joseph P, Anand Paramadhas BD, Reyes G, Maruatona MB, Chise M, Monokwane-Thupiso BB *et al*: **Healthcare-associated infections including neonatal bloodstream infections in a leading tertiary hospital in Botswana.** *Hospital practice (1995)* 2019, **47**(4):203-210.
170. Msem O, Mbwana J, Mahende C, Malabeja A, Gesase S, Crump JA *et al*: **Epidemiology and Antimicrobial Susceptibility of *Salmonella enterica* Bloodstream Isolates Among Febrile Children in a Rural District in Northeastern Tanzania: A Cross-sectional Study.** *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America* 2019, **68**(Suppl 2):S177-s182.
171. Müller-Schulte E, Tuo MN, Akoua-Koffi C, Schaumburg F, Becker SL: **High prevalence of ESBL-producing *Klebsiella pneumoniae* in clinical samples from central Côte d'Ivoire.** *International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases* 2020, **91**:207-209.
172. Mulu W, Yizengaw E, Alemu M, Mekonnen D, Hailu D, Ketemaw K *et al*: **Pharyngeal colonization and drug resistance profiles of *Moraxella catarrhalis*, *Streptococcus pneumoniae*, *Staphylococcus aureus*, and *Haemophilus influenzae* among HIV infected children attending ART Clinic of Felegehiwot Referral Hospital, Ethiopia.** *PloS one* 2018, **13**(5):e0196722.
173. Mulu W, Abera B, Yimer M, Hailu T, Ayele H, Abate D: **Bacterial agents and antibiotic resistance profiles of infections from different sites that occurred among patients at Debre Markos Referral Hospital, Ethiopia: a cross-sectional study.** *BMC research notes* 2017, **10**(1):254.
174. Musyoki VM, Masika MM, Mutai W, Wilfred G, Kuria A, Muthini F: **Antimicrobial susceptibility pattern of *Acinetobacter* isolates from patients in Kenyatta National Hospital, Nairobi, Kenya.** *The Pan African medical journal* 2019, **33**:146.
175. Mutai WC, Muigai AWT, Waiyaki P, Kariuki S: **Multi-drug resistant *Salmonella enterica* serovar Typhi isolates with reduced susceptibility to ciprofloxacin in Kenya.** *BMC microbiology* 2018, **18**(1):187.
176. Mutonga DM, Mureithi MW, Ngugi NN, Otieno FCF: **Bacterial isolation and antibiotic susceptibility from diabetic foot ulcers in Kenya using microbiological tests and comparison with RT-PCR in detection of *S. aureus* and MRSA.** *BMC research notes* 2019, **12**(1):244.
177. Nabti LZ, Sahli F, Radji N, Mezagha W, Semara L, Aberkane S *et al*: **High Prevalence of Multidrug-Resistant *Escherichia coli* in Urine Samples from Inpatients and Outpatients at a Tertiary Care Hospital in Sétif, Algeria.** *Microbial drug resistance (Larchmont, NY)* 2019, **25**(3):386-393.
178. Nacht C, Agingu W, Otieno F, Odhiambo F, Mehta SD: **Antimicrobial resistance patterns in *Neisseria gonorrhoeae* among male clients of a sexually transmitted infections clinic in Kisumu, Kenya.** *International journal of STD & AIDS* 2020, **31**(1):46-52.
179. Negash AA, Asrat D, Abebe W, Hailemariam T, Hailu T, Aseffa A *et al*: **Bacteremic Community-Acquired Pneumonia in Ethiopian Children: Etiology, Antibiotic Resistance, Risk Factors, and Clinical Outcome.** *Open forum infectious diseases* 2019, **6**(3):ofz029.

180. Ngalani OJT, Mbaveng AT, Marbou WJT, Ngai RY, Kuete V: **Antibiotic Resistance of Enteric Bacteria in HIV-Infected Patients at the Banka Ad-Lucem Hospital, West Region of Cameroon.** *The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale* 2019, **2019**:9381836.
181. Ngalani OJ, Marbou WJ, Mbaveng AT, Kuete V: **Immunological Profile and Bacterial Drug Resistance in Pregnant Women: A Cross Sectional Study.** *Osong public health and research perspectives* 2020, **11**(5):319-326.
182. Nigussie D, Amsalu A: **Prevalence of uropathogen and their antibiotic resistance pattern among diabetic patients.** *Turkish journal of urology* 2017, **43**(1):85-92.
183. Nkembe NM, Kamga HG, Baiye WA, Chafa AB, Njotang PN: **Streptococcus agalactiae prevalence and antimicrobial susceptibility pattern in vaginal and anorectal swabs of pregnant women at a tertiary hospital in Cameroon.** *BMC research notes* 2018, **11**(1):480.
184. Nzalie RN, Gonsu HK, Koulla-Shiro S: **Bacterial Etiology and Antibiotic Resistance Profile of Community-Acquired Urinary Tract Infections in a Cameroonian City.** *International journal of microbiology* 2016, **2016**:3240268.
185. Ogundare EO, Dedeke IOF, Okeniyi JA, Adeyemi LA, Ogunlesi TA and Oyelami OA: **Neonatal Septicaemia in a Rural Nigerian Hospital: Aetiology, Presentation and Antibiotic Sensitivity Pattern.** *British Journal of Medicine & Medical Research* 2015, **12**(7).
186. Olowo-Okere A, Ibrahim YKE, Olayinka BO, Ehinmidu JO, Mohammed Y, Nabti LZ *et al*: **Phenotypic and genotypic characterization of clinical carbapenem-resistant Enterobacteriaceae isolates from Sokoto, northwest Nigeria.** *New microbes and new infections* 2020, **37**:100727.
187. Onanuga A, Selekere TL: **Virulence and antimicrobial resistance of common urinary bacteria from asymptomatic students of Niger Delta University, Amassoma, Bayelsa State, Nigeria.** *Journal of pharmacy & bioallied sciences* 2016, **8**(1):29-33.
188. Ouchar M, Tidjani A, Lounnas M, Hide M, Benavides J, Somasse C *et al*: **Fecal carriage of extended-spectrum β -lactamase-producing Enterobacteriaceae in hospital and community settings in Chad.** *Antimicrobial resistance and infection control* 2019, **8**:169.
189. Ouedraogo AS, Sanou M, Kissou A, Sanou S, Solaré H, Kaboré F *et al*: **High prevalence of extended-spectrum β -lactamase producing enterobacteriaceae among clinical isolates in Burkina Faso.** *BMC infectious diseases* 2016, **16**:326.
190. Ouédraogo AS, Sanou S, Kissou A, Poda A, Aberkane S, Bouzinbi N *et al*: **Fecal Carriage of Enterobacteriaceae Producing Extended-Spectrum Beta-Lactamases in Hospitalized Patients and Healthy Community Volunteers in Burkina Faso.** *Microbial drug resistance (Larchmont, NY)* 2017, **23**(1):63-70.
191. Quansah E, Amoah BP, Omane AD, Obiri-Yeboah D, Odarkor MR, Asmah E *et al*: **Geographical Distribution of β -Lactam Resistance among Klebsiella spp. from Selected Health Facilities in Ghana.** *Tropical medicine and infectious disease* 2019, **4**(3).
192. Regasa Dadi B, Abebe T, Zhang L, Mihret A, Abebe W, Amogne W: **Drug resistance and plasmid profile of uropathogenic Escherichia coli among urinary tract infection patients in Addis Abeba.** *Journal of infection in developing countries* 2018, **12**(8):608-615.

193. Reta A, Wubie M, Mekuria G: **Nasal colonization and antimicrobial susceptibility pattern of *Staphylococcus aureus* among pre-school children in Ethiopia.** *BMC research notes* 2017, **10**(1):746.
194. Salama MSHAA, Marwa AM, Yasser IOF and Basma MA: **Group B streptococcal carriage, antimicrobial susceptibility, and virulence related genes among pregnant women in Alexandria, Egypt.** *Alexandria Journal of Medicine* 2017.
195. Seid M, Beyene G, Alemu Y, Workalemahu B, Delbo M, Tadesse D *et al*: **Does cotrimoxazole prophylaxis in HIV patients increase the drug resistance of pneumococci? A comparative cross-sectional study in southern Ethiopia.** *PLoS one* 2020, **15**(12):e0243054.
196. Shobo CO, Bester LA, Baijnath S, Somboro AM, Peer AK, Essack SY: **Antibiotic resistance profiles of *Campylobacter* species in the South Africa private health care sector.** *Journal of infection in developing countries* 2016, **10**(11):1214-1221.
197. Shobowale EO, Solarin AU, Elikwu CJ, Onyedibe KI, Akinola IJ, Faniran AA: **Neonatal sepsis in a Nigerian private tertiary hospital: Bacterial isolates, risk factors, and antibiotic susceptibility patterns.** *Annals of African medicine* 2017, **16**(2):52-58.
198. Signing AT, Marbou WJT, Penlap Beng V, Kuete V: **Antibiotic Resistance Profile of Uropathogenic Bacteria in Diabetic Patients at the Bafoussam Regional Hospital, West Cameroon Region.** *Cureus* 2020, **12**(7):e9345.
199. Simo Tchuinte PL, Rabenandrasana MAN, Kowalewicz C, Andrianoelina VH, Rakotondrasoa A, Andrianirina ZZ *et al*: **Phenotypic and molecular characterisations of carbapenem-resistant *Acinetobacter baumannii* strains isolated in Madagascar.** *Antimicrobial resistance and infection control* 2019, **8**:31.
200. Sorsa A, Früh J, Stötter L, Abdissa S: **Blood culture result profile and antimicrobial resistance pattern: a report from neonatal intensive care unit (NICU), Asella teaching and referral hospital, Asella, south East Ethiopia.** *Antimicrobial resistance and infection control* 2019, **8**:42.
201. Tack B, Phoba MF, Barbé B, Kalonji LM, Hardy L, Van Puyvelde Set *et al*: **Non-typhoidal *Salmonella* bloodstream infections in Kisantu, DR Congo: Emergence of O5-negative *Salmonella* Typhimurium and extensive drug resistance.** *PLoS neglected tropical diseases* 2020, **14**(4):e0008121.
202. Taitt CR, Leski TA, Erwin DP, Oundo EA, Kipkemoi NC, Ndonye JN *et al*: **Antimicrobial resistance of *Klebsiella pneumoniae* stool isolates circulating in Kenya.** *PloS one* 2017, **12**(6):e0178880.
203. Taye S, Getachew M, Desalegn Z, Biratu A, Mubashir K: **Bacterial profile, antibiotic susceptibility pattern and associated factors among pregnant women with Urinary Tract Infection in Goba and Sinana Woredas, Bale Zone, Southeast Ethiopia.** *BMC research notes* 2018, **11**(1):799.
204. Tayimetha CY, Unemo M: **Antimicrobial Susceptibility of *Neisseria gonorrhoeae* Isolates in Yaoundé, Cameroon From 2009 to 2014.** *Sexually transmitted diseases* 2018, **45**(12):e101-e103.
205. Tchiakpe E ZFM, Laurence C.Y, Honoré S.B, Bekou K.W, Esse A.M, Halimatou D.N *et al*: **Bacterial Distribution and Antibiotic Susceptibility Pattern of group B Streptococcus β hemolytic (GBS) in Vaginal Infections at Cotonou in Benin.** *American Journal of Infectious diseases and Microbiology* 2017, **5**(3).

206. Tefera Z, Mekonnen F, Tiruneh M, Belachew T: **Carriage rate of *Neisseria meningitidis*, antibiotic susceptibility pattern and associated risk factors among primary school children in Gondar town, Northwest Ethiopia.** *BMC infectious diseases* 2020, **20**(1):358.
207. Teklu DS, Negeri AA, Legese MH, Bedada TL, Woldemariam HK, Tullu KD: **Extended-spectrum beta-lactamase production and multi-drug resistance among Enterobacteriaceae isolated in Addis Ababa, Ethiopia.** *Antimicrobial resistance and infection control* 2019, **8**:39.
208. Tewelde medhin M, Saravanan M, Gebreyesus A, Gebreegziabiher D: **Ocular bacterial infections at Quiha Ophthalmic Hospital, Northern Ethiopia: an evaluation according to the risk factors and the antimicrobial susceptibility of bacterial isolates.** *BMC infectious diseases* 2017, **17**(1):207.
209. Toy T, Pak GD, Duc TP, Campbell JI, El Tayeb MA, Von Kalckreuth V *et al*: **Multicountry Distribution and Characterization of Extended-spectrum β -Lactamase-associated Gram-negative Bacteria From Bloodstream Infections in Sub-Saharan Africa.** *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America* 2019, **69**(Suppl 6):S449-s458.
210. Tuem KB, Desta R, Bitew H, Ibrahim S, Hishe HZ: **Antimicrobial resistance patterns of uropathogens isolated between 2012 and 2017 from a tertiary hospital in Northern Ethiopia.** *Journal of global antimicrobial resistance* 2019, **18**:109-114.
211. Wada FW, Tufa EG, Berheto TM, Solomon FB: **Nasopharyngeal carriage of *Streptococcus pneumoniae* and antimicrobial susceptibility pattern among school children in South Ethiopia: post-vaccination era.** *BMC research notes* 2019, **12**(1):306.
212. Woldemariam HK, Geleta DA, Tulu KD, Aber NA, Legese MH, Fenta GM *et al*: **Common uropathogens and their antibiotic susceptibility pattern among diabetic patients.** *BMC infectious diseases* 2019, **19**(1):43.
213. Yilema A, Moges F, Tadele S, Endris M, Kassu A, Abebe W *et al*: **Isolation of enterococci, their antimicrobial susceptibility patterns and associated factors among patients attending at the University of Gondar Teaching Hospital.** *BMC infectious diseases* 2017, **17**(1):276.
214. Zafer MM, El-Mahallawy HA, Abdulhak A, Amin MA, Al-Agamy MH, Radwan HH: **Emergence of colistin resistance in multidrug-resistant *Klebsiella pneumoniae* and *Escherichia coli* strains isolated from cancer patients.** *Annals of clinical microbiology and antimicrobials* 2019, **18**(1):40.
215. Zeynudin A, Pritsch M, Schubert S, Messerer M, Liegl G, Hoelscher M *et al*: **Prevalence and antibiotic susceptibility pattern of CTX-M type extended-spectrum β -lactamases among clinical isolates of gram-negative bacilli in Jimma, Ethiopia.** *BMC infectious diseases* 2018, **18**(1):524.
216. Kacou-N'douba A, Anné JC, Okpo LS, Elogne-Kouamé C, Koffi S, Koffi V *et al*: **Antimicrobial resistance of *Vibrio cholerae* O1 isolated during a cholera epidemic in 2011 in dry season in Côte d'Ivoire.** *Journal of infection in developing countries* 2012, **6**(7):595-597.
217. Eibach D, Herrera-León S, Gil H, Hogan B, Ehlkes L, Adjabeng M *et al*: **Molecular Epidemiology and Antibiotic Susceptibility of *Vibrio cholerae* Associated with a Large Cholera Outbreak in Ghana in 2014.** *PLoS neglected tropical diseases* 2016, **10**(5):e0004751.
218. Abana CZ, Sagoe KWC, Bonney EY, Maina EK, Aziati ID, Agbosu E *et al*: **Drug resistance mutations and viral load in human immunodeficiency virus type 2 and dual HIV-1/HIV-2 infected patients in Ghana.** *Medicine* 2019, **98**(6):e14313.
219. Adeniyi OV, Obi CL, Goon DT, Iweriebor B, Ajayi AI, Lambert J *et al*: **HIV-1 drug resistance surveillance among parturient women on anti-retroviral therapy in the Eastern Cape, South Africa.** *Journal of clinical virology* 2019, **113**:104-109.

Africa: Implications for elimination of mother-to-child transmission. *Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology* 2019, **117**:89-95.

220. Agegne M, Abera B, Derbie A, Yismaw G, Shiferaw MB: **Magnitude of Vancomycin-Resistant Enterococci (VRE) Colonization among HIV-Infected Patients Attending ART Clinic in West Amhara Government Hospitals.** *International journal of microbiology* 2018, **2018**:7510157.

221. Agwu AL, Warshaw MG, McFarland EJ, Siberry GK, Melvin AJ, Wiznia AA *et al*: **Decline in CD4 T lymphocytes with monotherapy bridging strategy for non-adherent adolescents living with HIV infection: Results of the IMPAACT P1094 randomized trial.** *PLoS one* 2017, **12**(6):e0178075.

222. Alaoui N, El Alaoui MA, El Annaz H, Farissi FZ, Alaoui AS, El Fahime E *et al*: **HIV-1 Integrase Resistance among Highly Antiretroviral Experienced Patients from Morocco.** *Intervirology* 2019, **62**(2):65-71.

223. Amstutz A, Nsakala BL, Vanobberghen F, Muhairwe J, Glass TR, Achieng B *et al*: **SESOTHO trial ("Switch Either near Suppression Or THOusand") - switch to second-line versus WHO-guided standard of care for unsuppressed patients on first-line ART with viremia below 1000 copies/mL: protocol of a multicenter, parallel-group, open-label, randomized clinical trial in Lesotho, Southern Africa.** *BMC infectious diseases* 2018, **18**(1):76.

224. Arimide DA, Abebe A, Kebede Y, Adugna F, Tilahun T, Kassa D *et al*: **HIV-genetic diversity and drug resistance transmission clusters in Gondar, Northern Ethiopia, 2003-2013.** *PLoS one* 2018, **13**(10):e0205446.

225. Ateba Ndongo F, Texier G, Ida Penda C, Tejokem MC, Tetang Ndiang S, Ndongo JA *et al*: **Virologic Response to Early Antiretroviral Therapy in HIV-infected Infants: Evaluation After 2 Years of Treatment in the Pediacam Study, Cameroon.** *The Pediatric infectious disease journal* 2018, **37**(1):78-84.

226. Awotiwon AA, Johnson S, Rutherford GW, Meintjes G, Eshun-Wilson I: **Primary antifungal prophylaxis for cryptococcal disease in HIV-positive people.** *The Cochrane database of systematic reviews* 2018, **8**(8):Cd004773.

227. Ayitewala A, Kyeyune F, Ainembabazi P, Nabulime E, Kato CD, Nankya I: **Comparison of HIV drug resistance profiles across HIV-1 subtypes A and D for patients receiving a tenofovir-based and zidovudine-based first line regimens in Uganda.** *AIDS research and therapy* 2020, **17**(1):2.

228. Ba S, Raugi DN, Smith RA, Sall F, Faye K, Hawes SE *et al*: **A Trial of a Single-tablet Regimen of Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Disoproxil Fumarate for the Initial Treatment of Human Immunodeficiency Virus Type 2 Infection in a Resource-limited Setting: 48-Week Results From Senegal, West Africa.** *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America* 2018, **67**(10):1588-1594.

229. Ba S, Dia-Badiane NM, Hawes SE, Deguenonvo LF, Sall F, Ndour CT *et al*: **[HIV-2 infection in Senegal: virological failures and resistance to antiretroviral drugs (ARVs)].** *The Pan African medical journal* 2019, **33**:222.

230. Baeten JM, Palanee-Phillips T, Brown ER, Schwartz K, Soto-Torres LE, Govender V *et al*: **Use of a Vaginal Ring Containing Dapivirine for HIV-1 Prevention in Women.** *The New England journal of medicine* 2016, **375**(22):2121-2132.

231. Barabona G, Mahiti M, Masoud S, Mbelele P, Mgunya AS, Minja L *et al*: **Pre-treatment and acquired HIV drug resistance in Dar es Salaam, Tanzania in the era of tenofovir and routine viral load monitoring.** *The Journal of antimicrobial chemotherapy* 2019, **74**(10):3016-3020.
232. Baumann A, Musaazi J, Kambugu A, Kälin M, Weissberg D, Ssemwanga D *et al*: **Virological Outcome of Patients With HIV Drug Resistance Attending an Urban Outpatient Clinic in Uganda: A Need for Structured Adherence Counseling and Third-Line Treatment Options.** *Journal of acquired immune deficiency syndromes (1999)* 2019, **80**(4):481-487.
233. Boltz VF, Shao W, Bale MJ, Halvas EK, Luke B, McIntyre JA *et al*: **Linked dual-class HIV resistance mutations are associated with treatment failure.** *JCI insight* 2019, **4**(19).
234. Fofana DB, d'Almeida M, Lambert-Niclot S, Peytavin G, Girard PM, Lafia B, Zohoun-Guidigbi L *et al*: **Resistance profile and treatment outcomes in HIV-infected children at virological failure in Benin, West Africa.** *The Journal of antimicrobial chemotherapy* 2018, **73**(11):3143-3147.
235. Grant-McAuley W, Fogel JM, Galai N, Clarke W, Bread A, Marzinke MA *et al*: **Antiretroviral drug use and HIV drug resistance in female sex workers in Tanzania and the Dominican Republic.** *PloS one* 2020, **15**(10):e0240890.
236. Jordan MR, Hamunime N, Bikinesi L, Sawadogo S, Agolory S, Shiningavamwe AN *et al*: **High levels of HIV drug resistance among adults failing second-line antiretroviral therapy in Namibia.** *Medicine* 2020, **99**(37):e21661.
237. Kozal M, Aberg J, Pialoux G, Cahn P, Thompson M, Molina JM *et al*: **Fostemsavir in Adults with Multidrug-Resistant HIV-1 Infection.** *The New England journal of medicine* 2020, **382**(13):1232-1243.
238. Matume ND, Tebit DM, Bessong PO: **HIV-1 subtype C predicted co-receptor tropism in Africa: an individual sequence level meta-analysis.** *AIDS research and therapy* 2020, **17**(1):5.
239. Moyo S, Hunt G, Zuma K, Zungu M, Marinda E, Mabaso M *et al*: **HIV drug resistance profile in South Africa: Findings and implications from the 2017 national HIV household survey.** *PloS one* 2020, **15**(11):e0241071.
240. Ngo-Giang-Huong N, Huynh THK, Dagnra AY, Toni TD, Maiga AI, Kania D *et al*: **Prevalence of pretreatment HIV drug resistance in West African and Southeast Asian countries.** *The Journal of antimicrobial chemotherapy* 2019, **74**(2):462-467.
241. Nyaku AN, Zheng L, Gulick RM, Olefsky M, Berzins B, Wallis CL *et al*: **Dolutegravir plus lamivudine for initial treatment of HIV-1-infected participants with HIV-1 RNA <500 000 copies/mL: week 48 outcomes from ACTG 5353.** *The Journal of antimicrobial chemotherapy* 2019, **74**(5):1376-1380.
242. Orkin C, Squires KE, Molina JM, Sax PE, Wong WW, Sussmann O *et al*: **Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate is Non-inferior to Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-naïve Adults With Human Immunodeficiency Virus-1 Infection: Week 48 Results of the DRIVE-AHEAD Trial.** *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America* 2019, **68**(4):535-544.
243. Riddler SA, Balkus JE, Parikh UM, Mellors JW, Akello C, Dadabhai S *et al*: **Clinical and Virologic Outcomes Following Initiation of Antiretroviral Therapy Among Seroconverters in the Microbicide Trials Network-020 Phase III Trial of the Dapivirine Vaginal Ring.** *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America* 2019, **69**(3):523-529.

244. Rutstein SE, Chen JS, Nelson JAE, Phiri S, Miller WC, Hosseinpour MC: **High rates of transmitted NNRTI resistance among persons with acute HIV infection in Malawi: implications for first-line dolutegravir scale-up.** *AIDS research and therapy* 2019, **16**(1):5.
245. Sebastião CS, Neto Z, de Jesus CS, Mirandela M, Jandondo D, Couto-Fernandez JC *et al*: **Genetic diversity and drug resistance of HIV-1 among infected pregnant women newly diagnosed in Luanda, Angola.** *PloS one* 2019, **14**(11):e0225251.
246. Tadesse BT, Tsai O, Chala A, Chaka TE, Eromo T, Lapointe HR *et al*: **Prevalence and Correlates of Pre-Treatment HIV Drug Resistance among HIV-Infected Children in Ethiopia.** *Viruses* 2019, **11**(9).
247. Takou D, Fokam J, Teto G, Santoro MM, Ceccherini-Silberstein F, Nanfack AJ *et al*: **HIV-1 drug resistance testing is essential for heavily-treated patients switching from first- to second-line regimens in resource-limited settings: evidence from routine clinical practice in Cameroon.** *BMC infectious diseases* 2019, **19**(1):246.
248. Tchounga BK, Charpentier C, Coffie PA, Dabis F, Descamps D, Eholie SP, Ekouevi DK: **Survival among antiretroviral-experienced HIV-2 patients experiencing virologic failure with drug resistance mutations in Cote d'Ivoire West Africa.** *PloS one* 2020, **15**(8):e0236642.
249. Udeze AO, Olaleye DO, Odaibo GN: **Polymorphisms and drug resistance analysis of HIV-1 isolates from patients on first line antiretroviral therapy (ART) in South-eastern Nigeria.** *PloS one* 2020, **15**(4):e0231031.
250. Venter WDF, Moorhouse M, Sokhela S, Fairlie L, Mashabane N, Masenya M *et al*: **Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV.** *The New England journal of medicine* 2019, **381**(9):803-815.
251. Yendewa GA, Sahr F, Lakoh S, Ruiz M, Patiño L, Tabernilla A, Deen GF *et al*: **Prevalence of drug resistance mutations among ART-naive and -experienced HIV-infected patients in Sierra Leone.** *The Journal of antimicrobial chemotherapy* 2019, **74**(7):2024-2029.
252. Zupin L, Polesello V, Segat L, Kamada AJ, Kuhn L, Crovella S: **DEFB1 polymorphisms and HIV-1 mother-to-child transmission in Zambian population.** *The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstet* 2019, **32**(17):2805-2811.
253. Gupta-Wright A, Fielding K, van Oosterhout JJ, Alufandika M, Grint DJ, Chimbayo E, Heaney J *et al*: **Virological failure, HIV-1 drug resistance, and early mortality in adults admitted to hospital in Malawi: an observational cohort study.** *The lancet HIV* 2020, **7**(9):e620-e628.
254. Ssemwanga D, Lihana RW, Ugoji C, Abimiku A, Nkengasong J, Dakum P *et al*: **Update on HIV-1 acquired and transmitted drug resistance in Africa.** *AIDS reviews* 2015, **17**(1):3-20.
255. Bedewi Omer Z, Mekonnen Y, Worku A, Zewde A, Medhin G, Mohammed T *et al*: **Evaluation of the GenoType MTBDRplus assay for detection of rifampicin- and isoniazid-resistant Mycobacterium tuberculosis isolates in central Ethiopia.** *International journal of mycobacteriology* 2016, **5**(4):475-481.
256. E. Ahiarakwem I, Ekejindu IM, Akujobi CN, Aghanya IN: **Multidrug-resistant tuberculosis in Imo State, Southeast, Nigeria.** *Nigerian journal of clinical practice* 2020, **23**(8):1172-1177.

257. Albert H, Purcell R, Wang YY, Kao K, Mareka M, Katz Z *et al*: **Designing an optimized diagnostic network to improve access to TB diagnosis and treatment in Lesotho.** *PLoS one* 2020, **15**(6):e0233620.
258. Bouzinbi N, Marcy O, Bertolotti T, Chiron R, Bemer P, Pestel-Caron M *et al*: **Evaluation of the GenoType NTM-DR assay performance for the identification and molecular detection of antibiotic resistance in *Mycobacterium abscessus* complex.** *PLoS one* 2020, **15**(9):e0239146.
259. Furin J, Loveday M, Hlangu S, Dickson-Hall L, le Roux S, Nicol M, Cox H: "A very humiliating illness": a qualitative study of patient-centered Care for Rifampicin-Resistant Tuberculosis in South Africa. *BMC public health* 2020, **20**(1):76.
260. Kuaban C, Toukam LDI, Sander M: **Treatment outcomes and factors associated with unfavourable outcome among previously treated tuberculosis patients with isoniazid resistance in four regions of Cameroon.** *The Pan African medical journal* 2020, **37**:45.
261. Molina JM, Squires K, Sax PE, Cahn P, Lombaard J, DeJesus E *et al*: **Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial.** *The lancet HIV* 2020, **7**(1):e16-e26.
262. Naluyange R, Mboowa G, Komakech K, Semugenze D, Kateete DP, Ssengooba W: **High prevalence of phenotypic pyrazinamide resistance and its association with pncA gene mutations in *Mycobacterium tuberculosis* isolates from Uganda.** *PLoS one* 2020, **15**(5):e0232543.
263. Nimmo C, Millard J, van Dorp L, Brien K, Moodley S, Wolf A *et al*: **Population-level emergence of bedaquiline and clofazimine resistance-associated variants among patients with drug-resistant tuberculosis in southern Africa: a phenotypic and phylogenetic analysis.** *The Lancet Microbe* 2020, **1**(4):e165-e174.
264. Schwoebel V, Trébucq A, Kashongwe Z, Bakayoko AS, Kuaban C, Noeske J *et al*: **Outcomes of a nine-month regimen for rifampicin-resistant tuberculosis up to 24 months after treatment completion in nine African countries.** *EClinicalMedicine* 2020, **20**:100268.
265. Tilahun M, Shimelis E, Wogayehu T, Assefa G, Wondimagegn G, Mekonnen A *et al*: **Molecular detection of multidrug resistance pattern and associated gene mutations in *M. tuberculosis* isolates from newly diagnosed pulmonary tuberculosis patients in Addis Ababa, Ethiopia.** *PLoS one* 2020, **15**(8):e0236054.
266. Walt MV, Masuku S, Botha S, Nkwenika T, Keddy KH: **Retrospective record review of pregnant women treated for rifampicin-resistant tuberculosis in South Africa.** *PLoS one* 2020, **15**(9):e0239018.
267. Wasihun AG, Dejene TA, Hailu GG: **Frequency of MTB and rifampicin resistance MTB using Xpert-MTB/RIF assay among adult presumptive tuberculosis patients in Tigray, Northern Ethiopia: A cross sectional study.** *PLoS one* 2020, **15**(11):e0240361.
268. Grandesso F, Guindo O, Woi Messe L, Makarimi R, Traore A, Dama S *et al*: **Efficacy of artesunate-amodiaquine, dihydroartemisinin-piperaquine and artemether-lumefantrine for the treatment of uncomplicated *Plasmodium falciparum* malaria in Maradi, Niger.** *Malaria journal* 2018, **17**(1):52.
269. Adegbite BR, Edoa JR, Honkpehedji YJ, Zinsou FJ, Dejon-Agobe JC, Mbong-Ngwe M *et al*: **Monitoring of efficacy, tolerability and safety of artemether-lumefantrine and artesunate-**

amodiaquine for the treatment of uncomplicated *Plasmodium falciparum* malaria in Lambaréné, Gabon: an open-label clinical trial. *Malaria journal* 2019, **18**(1):424.

270. Ayalew MB: **Therapeutic efficacy of artemether-lumefantrine in the treatment of uncomplicated *Plasmodium falciparum* malaria in Ethiopia: a systematic review and meta-analysis.** *Infectious diseases of poverty* 2017, **6**(1):157.

271. Beyene HB, Beyene MB, Ebstie YA, Desalegn Z: **Efficacy of Chloroquine for the Treatment of Vivax malaria in Northwest Ethiopia.** *PLoS one* 2016, **11**(8):e0161483.

272. Diallo MA, Yade MS, Ndiaye YD, Diallo I, Diougue K, Sy SA *et al*: **Efficacy and safety of artemisinin-based combination therapy and the implications of Pfkelch13 and Pfcoronin molecular markers in treatment failure in Senegal.** *Scientific reports* 2020, **10**(1):8907.

273. Fançony C, Brito M, Gil JP: ***Plasmodium falciparum* drug resistance in Angola.** *Malaria journal* 2016, **15**:74.

274. Hill J, Hoyt J, Achieng F, Ouma P, L'Lanziva A, Kariuki S, Desai M *et al*: **User and Provider Acceptability of Intermittent Screening and Treatment and Intermittent Preventive Treatment with Dihydroartemisinin-Piperaquine to Prevent Malaria in Pregnancy in Western Kenya.** *PLoS one* 2016, **11**(3):e0150259.

275. Maharaj R, Kissoon S, Lakan V, Kheswa N: **Rolling back malaria in Africa - challenges and opportunities to winning the elimination battle.** *South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde* 2019, **109**(11b):53-56.

276. Mandara CI, Kavishe RA, Gesase S, Mghamba J, Ngadaya E, Mmbuji P *et al*: **High efficacy of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated falciparum malaria in Muheza and Kigoma Districts, Tanzania.** *Malaria journal* 2018, **17**(1):261.

277. Onyamboko MA, Hoglund RM, Lee SJ, Kabedi C, Kayembe D, Bajjanga BB *et al*: **A Randomized Controlled Trial of Three- versus Five-Day Artemether-Lumefantrine Regimens for Treatment of Uncomplicated *Plasmodium falciparum* Malaria in Pregnancy in Africa.** *Antimicrobial agents and chemotherapy* 2020, **64**(3).

278. Rasmussen SA, Ceja FG, Conrad MD, Tumwebaze PK, Byaruhanga O, Katairo T *et al*: **Changing Antimalarial Drug Sensitivities in Uganda.** *Antimicrobial agents and chemotherapy* 2017, **61**(12).

279. Tinto H, Valea I, Ouédraogo JB, Guiguemdé TR: **Lessons learnt from 20 years surveillance of malaria drug resistance prior to the policy change in Burkina Faso.** *Annals of parasitology* 2016, **62**(1):17-24.

280. van Eijk AM, Larsen DA, Kayentao K, Koshy G, Slaughter DEC, Roper C *et al*: **Effect of *Plasmodium falciparum* sulfadoxine-pyrimethamine resistance on the effectiveness of intermittent preventive therapy for malaria in pregnancy in Africa: a systematic review and meta-analysis.** *The Lancet Infectious diseases* 2019, **19**(5):546-556.

281. Warsame M, Hassan AM, Hassan AH, Jibril AM, Khim N, Arale AM *et al*: **High therapeutic efficacy of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated falciparum malaria in Somalia.** *Malaria journal* 2019, **18**(1):231.

282. Yeka A, Wallender E, Mulebeke R, Kibuuka A, Kigozi R, Bosco A *et al*: **Comparative Efficacy of Artemether-Lumefantrine and Dihydroartemisinin-Piperaquine for the Treatment of**

Uncomplicated Malaria in Ugandan Children. *The Journal of infectious diseases* 2019, **219**(7):1112-1120.

283. Uwimana A, Legrand E, Stokes BH, Ndikumana JM, Warsame M, Umulisa N *et al*: **Emergence and clonal expansion of in vitro artemisinin-resistant *Plasmodium falciparum* kelch13 R561H mutant parasites in Rwanda.** *Nature medicine* 2020, **26**(10):1602-1608.

284. Tacconelli E, Carrara E, Savoldi A, Harbarth S, Mendelson M, Monnet DL *et al*: **Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis.** *The Lancet Infectious diseases* 2018, **18**(3):318-327.

285. Gera T, Shah D, Garner P, Richardson M, Sachdev HS: **Integrated management of childhood illness (IMCI) strategy for children under five.** *The Cochrane database of systematic reviews* 2016(6):Cd010123.

286. Vasan A, Ellner A, Lawn SD, Gove S, Anatole M, Gupta N *et al*: **Integrated care as a means to improve primary care delivery for adults and adolescents in the developing world: a critical analysis of Integrated Management of Adolescent and Adult Illness (IMAI).** *BMC medicine* 2014, **12**:6.

287. Ramamurthy T, Mutreja A, Weill FX, Das B, Ghosh A, Nair GB: **Corrigendum: Revisiting the Global Epidemiology of Cholera in Conjunction With the Genomics of *Vibrio cholerae*.** *Frontiers in public health* 2019, **7**:237.

288. Salim A, Lan R, Reeves PR: ***Vibrio cholerae* pathogenic clones.** *Emerging infectious diseases* 2005, **11**(11):1758-1760.

289. Dalsgaard A, Forslund A, Petersen A, Brown DJ, Dias F, Monteiro S *et al*: **Class 1 integron-borne, multiple-antibiotic resistance encoded by a 150-kilobase conjugative plasmid in epidemic *vibrio cholerae* O1 strains isolated in Guinea-Bissau.** *Journal of clinical microbiology* 2000, **38**(10):3774-3779.

290. Kitaoka M, Miyata ST, Unterweger D, Pukatzki S: **Antibiotic resistance mechanisms of *Vibrio cholerae*.** *Journal of medical microbiology* 2011, **60**(Pt 4):397-407.

291. Siriphap A, Leekitcharoenphon P, Kaas RS, Theethakaew C, Aarestrup FM, Sutheinkul O *et al*: **Characterization and Genetic Variation of *Vibrio cholerae* Isolated from Clinical and Environmental Sources in Thailand.** *PloS one* 2017, **12**(1):e0169324.

292. Horo K, Koffi NB, Kouassi BA, Brou-Godé VC, Ahui BJ, Silué Y *et al*: **[Antituberculous retreatement in case of failure to category I regimen].** *Revue des maladies respiratoires* 2010, **27**(9):1055-1061.

293. Veiga MI, Dhingra SK, Henrich PP, Straimer J, Gnädig N, Uhlemann AC *et al*: **Globally prevalent PfMDR1 mutations modulate *Plasmodium falciparum* susceptibility to artemisinin-based combination therapies.** *Nature communications* 2016, **7**:11553.



ANNEXES

Annex 1: Final list of selected articles and associated data

Link: [..\..\..\Annex 1_Final list of selected articles and associated data.xlsx](#)

Annex 2: Data characteristics

Characteristic	Frequency (%)
Publication year	
2016	25 (14.8)
2017	39 (23.2)
2018	42 (25)
2019	38 (22.6)
2020	23 (13.7)
End data collection period	
Before 2016	84 (50)
Between 2016-2018	65 (38.7)
Between 2019-2020	12 (7.1)
Not mentioned	10 (5.9)
African country	
Algeria	7 (4.2)
Angola	2 (1.2)
Benin	1 (0.5)
Botswana	1 (0.6)
Burkina Faso	4 (2.4)
Cameroun	11 (6.5)
CAR	1 (0.6)
Chad	2 (1.2)
Eritrea	1 (0.6)
Ethiopia	76 (45.2)
Gambia	1 (0.6)
Ghana	12 (7.1)
Ivory cost	1 (0.6)
Kenya	12 (7.1)
Madagascar	1 (0.6)
Malawi	2 (1.2)
Mali	1 (0.6)
Mozambique	1 (0.6)
Nigeria	9 (5.4)
Rwanda	1 (0.6)
South Africa	5 (2.9)
Tanzania	3 (1.8)
The DRC	4 (2.4)
Uganda	5 (2.9)
Zambia	2 (1.2)
In more than one African country	4 (2.4)

Characteristic	Frequency (%)
Study design	
Case control	1 (0.6)
Longitudinal	1 (0.6)
Cross-sectional	87 (51.7)
Observational	3 (1.8)
Prospective	12 (7.1)
Retrospective	9 (5.4)
Surveillance	4 (2.4)
Not mentioned	71 (42.3)
Source of Data	
Inpatient	10 (5.9)
outpatient	8 (4.7)
Both	26 (15.5)
NA	3 (1.7)
Not mentioned	146 (86.9)
Investigation method	
Phenotypic	123 (73.7)
Phenotypic & Genotypic	44 (26.3)
Source of infection	
Hospital acquired	5 (2.9)
Community acquired	4 (2.4)
Both	3 (1.8)
NA	5 (2.9)
Not mentioned	171 (10.1)
AST guidelines	
BSAC	2 (1.2)
CA-SFM	7 (4.2)
CA-SFM & EUCAST	2 (1.2)
CLSI	137 (81.5)
CLSI & BSAC	1 (0.6)
CLSI & EUCAST	8 (4.7)
EUCAST	19 (11.3)
Not mentioned	12 (7.1)
AST Methods	
Broth microdilution	2 (1.2)
Disc diffusion	115 (68.5)
Disc diffusion & broth microdilution	4 (2.4)
Disc diffusion & E-test	12 (7.1)
Disc diffusion & MIC	23 (13.7)

Characteristic	Frequency (%)
Disc diffusion & VITEK	1 (0.6)
Disc diffusion, D-test & VITEK	1 (0.6)
Disc diffusion, E-test & MIC	2 (1.06)
Disc diffusion, broth microdilution & MIC	1 (0.6)
E-test	4 (2.1)
NA	2 (1.06)
Not mentioned	5 (2.6)
PHX system	1 (0.6)
VITEK	13 (7.7)
VITEK & E-test	1 (0.6)
VITEK & MALDI-ToF	1 (0.6)
VITEK, broth microdilution & E-test	1 (0.6)
Bacterial identification methods	
BACT/ALERT	4 (2.4)
BACT/ALERT & API	1 (0.6)
BACTEC	4 (2.4)
BACTEC & API	3 (1.8)
BACTEC & MALDI-ToF	1 (0.6)
BACTEC, API & VITEK	1 (0.6)
BACTEC, BACT/ALERT & API	2 (1.2)
Conventional BC	1 (0.6)
NA	1 (0.6)
Not mentioned	4 (2.4)
Standard microbiological culture & API	20 (11.9)
Standard microbiological culture & MALDI-ToF	11 (6.5)
Standard microbiological culture	105 (62.5)
Standard microbiological culture & BACTEC	1 (0.6)
Standard microbiological culture & CAMP Test	6 (3.5)
Standard microbiological culture & Hodge test	1 (0.6)
Standard microbiological culture & Vibrio cholera TM Difco BD	1 (0.6)
Standard microbiological culture & VITEK	10 (5.9)
Standard microbiological culture, API & MALDI-ToF	4 (2.4)
Standard microbiological culture, API & VITEK	1 (0.6)
Standard microbiological culture, CAMP test, modified Hodge Test & CIM	1 (0.6)
VITEK	5 (2.9)
CAR: Central African Republic; DRC: Democratic Republic of the Congo; NA: not applicable	

Annex 3: Total number (%) of reported bacteria isolates per disease or infection in Africa, 2016-2020

Bacteria isolate	BSI n (%)	Ear infection n (%)	Enteric fever n (%)	Gastroenteritis n (%)	Meningitis n (%)	Invasive Salmonellosis n (%)	Ocular infection n (%)	Skin infection n (%)	UTI n (%)	Wound infection n (%)	Total
<i>Acinetobacter baumannii</i>	1472 (65.9)	NA	NA	NA	NA	NA	NA	NA	NA	744 (33.3)	2216
<i>Escherichia coli</i>	599 (49.8)	NA	NA	393 (32.5)	NA	NA	NA	NA	201 (17)	NA	1193
<i>Group A Streptococcus</i>	1052 (75)	NA	NA	NA	NA	NA	NA	NA	NA	350 (25)	1402
<i>Klebsiella spp.</i>	17397 (67.2)	NA	NA	9 (0.03)	NA	NA	NA	NA	NA	8482 (32.7)	25888
<i>Proteus mirabilis</i>	3531 (39)	NA	NA	NA	NA	NA	NA	NA	5540 (61)	NA	9071
<i>Pseudomonas spp.</i>	505 (38.5)	167 (12.6)	NA	NA	NA	NA	NA	NA	450 (34)	191 (14.4)	1313
<i>Salmonella Typhi</i>	4062 (64)	NA	732 (11.6)	801 (12.6)	NA	734 (11.6)	NA	NA	NA	NA	6329
Non-typhoidal <i>Salmonella</i> serovars	7037 (50.4)	NA	NA	NA	NA	6930 (49.6)	NA	NA	NA	NA	13967
<i>Shigella spp.</i>	1735 (74.3)	NA	NA	600 (25.7)	NA	NA	NA	NA	NA	NA	2335
<i>Staphylococcus aureus</i>	27534 (62.6)	NA	NA	NA	NA	NA	198 (0.5)	98 (0.2)	NA	16096 (36.6)	43913
<i>Streptococcus spp.</i>	5315 (68.4)	615 (7.9)	NA	NA	NA	NA	737 (9.5)	625 (8)	NA	481 (62)	7773

Gastroenteritis combines data for both gastroenteritis and Diarrhea; NA means that there is no reported isolate for the considered bacteria for that specific disease or infection; BSI: Bacterial bloodstream infection; STI: Sexually Transmitted Infection and UTI: Urinary Tract Infection.

Annex 4: Summary AMR per country, region and type of sample in Africa, GLASS report, 2016-2018

Bacteria isolate	Country	African Region	N. bacteria isolates	Type of sample			
				Blood n (%)	Genital n (%)	Stool n (%)	Urine n (%)
<i>Acinetobacter</i>	Ethiopia, Malawi, Mali, Nigeria, South Africa, Zambia	East, Southern & Western Africa	27674	27674 (100)	0 (0)	0	0 (0)
<i>Escherichia coli</i>	Ethiopia, Madagascar, Malawi, Mali, Nigeria, South Africa, Uganda & Zambia	East, southern & Western Africa	82627	48417 (58.6)	0 (0)	0 (0)	34210 (41.4)
<i>Klebsiella pneumoniae</i>	Madagascar, Malawi, Zambia, Nigeria, Uganda, Ethiopia, Mali, Mozambique, Nigeria & South Africa	East, southern & Western Africa	83389	73389 (88)	0 (0)	0 (0)	10000 (12)
<i>Neisseria gonorrhoeae</i>	Madagascar, Malawi, Uganda, South Africa	East & Southern Africa	11893	0 (0)	11893 (100)	0 (0)	0 (0)
<i>Salmonella</i> spp.	Malawi, Mali, Nigeria, South Africa, Uganda & Zambia	East, southern & Western Africa	16447	7418 (45.1)	0 (0)	9029 (54.9)	0 (0)
<i>Shigella</i> spp.	Madagascar, Malawi, South Africa & Uganda	East & Southern Africa	5575	0 (0)	0 (0)	5575 (100)	0 (0)
<i>Staphylococcus aureus</i>	Madagascar, Malawi, Mali, Mozambique, Nigeria, South Africa & Uganda	East, southern & Western Africa	10700	10700 (100)	0 (0)	0 (0)	0 (0)
<i>Streptococcus pneumoniae</i>	Malawi, Mali &South Africa	Southern & Western Africa	10700	10700 (100)	0 (0)	0 (0)	0 (0)

Annex 5: Percentage AMR genetic markers among gram-negative and gram-positive bacterial isolates in Africa, 2016-2020.

Bacteria	ESBL			Metallo- β -lactamase					Carbapenemase	MRSA	DCS	
	<i>blaCTX-M</i> n(%)	<i>blaTEM</i> n(%)	<i>blaSHV</i> n(%)	<i>blaNDM</i> n(%)	<i>blaSPM</i> n (%)	<i>oprD</i> n(%)	<i>blaIMP</i> n(%)	<i>PSE</i> n(%)	<i>blaOXA</i> n(%)	<i>SCCmec</i> n(%)	<i>gyrA</i> mutation n(%)	<i>gyrB</i> mutation n(%)
<i>Klebsiella pneumoniae</i>	522(60.3)	203(51%)	604(70)	1003(90%)					242(43.2)			
<i>Escherichia coli</i>	343(28.8)	191(43%)	200(30%)						336(49)			
<i>Staphylococcus aureus</i>										116 (21.4)		
<i>Salmonella Typhi</i>											487(25)	176(7.8)
<i>Pseudomonas aeruginosa</i>					305(70)	53(10)	26(5)	14(2.5)				